
Paper II

***Biomarker profiles in serum and saliva of experimental Sjögren's
syndrome - associations with specific autoimmune manifestations
(2008)***

Arthritis Research & Therapy 10:R22

Research article

Open Access

Biomarker profiles in serum and saliva of experimental Sjögren's syndrome: associations with specific autoimmune manifestationsNicolas Delaleu¹, Heike Immervoll^{2,3}, Janet Cornelius⁴ and Roland Jonsson^{1,5,6}¹Broegelmann Research Laboratory, The Gade Institute, University of Bergen, Haukelandsveien, Bergen 5021, Norway²Section of Pathology, The Gade Institute, University of Bergen, Jonas Liesvei, Bergen 5021, Norway³Department of Pathology, Haukeland University Hospital, Jonas Liesvei, Bergen 5021, Norway⁴Department of Pathology, Immunology and Laboratory Medicine, University of Florida, SW Archer Road, Gainesville, FL 32610, USA⁵Department of Rheumatology, Haukeland University Hospital, Bergen, Jonas Liesvei, Bergen 5021, Norway⁶Department of Otolaryngology, Head and Neck Surgery, Haukeland University Hospital, Bergen, Jonas Liesvei, Bergen 5021, NorwayCorresponding author: Nicolas Delaleu, nicolas.delaleu@gades.uib.no

Received: 28 Nov 2007 Revisions requested: 8 Jan 2008 Revisions received: 5 Feb 2008 Accepted: 20 Feb 2008 Published: 20 Feb 2008

Arthritis Research & Therapy 2008, **10**:R22 (doi:10.1186/ar2375)This article is online at: <http://arthritis-research.com/content/10/1/R22>© 2008 Delaleu *et al.*; licensee BioMed Central Ltd.This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.**Abstract**

Introduction Sjögren's syndrome (SS) is a systemic autoimmune disease that mainly targets the exocrine glands. The aim of this study was to investigate the involvement of 87 proteins measured in serum and 75 proteins analyzed in saliva in spontaneous experimental SS. In addition, we intended to compute a model of the immunological situation representing the overt disease stage of SS.

Methods Nondiabetic, nonobese diabetic (NOD) mice aged 21 weeks were evaluated for salivary gland function, salivary gland inflammation and extraglandular disease manifestations. The analytes, comprising chemokines, cytokines, growth factors, autoantibodies and other biomarkers, were quantified using multi-analyte profile technology and fluorescence-activated cell sorting. Age-matched and sex-matched Balb/c mice served as a reference.

Results We found NOD mice to exhibit impaired salivary flow, glandular inflammation and increased secretory SSB (anti-La) levels. Thirty-eight biomarkers in serum and 34 in saliva obtained

from NOD mice were significantly different from those in Balb/c mice. Eighteen biomarkers in serum and three chemokines measured in saliva could predict strain membership with 80% to 100% accuracy. Factor analyses identified principal components mostly correlating with one clinical aspect of SS and having distinct associations with components extracted from other families of proteins.

Conclusion Autoimmune manifestations of SS are greatly independent and associated with various immunological processes. However, CD40, CD40 ligand, IL-18, granulocyte chemotactic protein-2 and anti-muscarinic M3 receptor IgG₃ may connect the different aspects of SS. Processes related to the adaptive immune system appear to promote SS with a strong involvement of T-helper-2 related proteins in hyposalivation. This approach further established saliva as an attractive biofluid for biomarker analyses in SS and provides a basis for the comparison and selection of potential drug targets and diagnostic markers.

Introduction

Over recent decades the immune system has been subject to much investigation. Growing complexity has often been a major byproduct of the discoveries reported, and subse-

quently models were established to cope with such complexity. Regarding autoimmune diseases in general, and Sjögren's syndrome (SS) in particular, verifying and expanding such models is desirable, because it has proved difficult to extrapo-

CD40L = CD40 ligand; CXCL = C-X-C chemokine ligand; DA = discriminant analyses; FITC = fluorescein isothiocyanate; FS = focus score; GCP = granulocyte chemotactic protein; IL = interleukin; IP = inducible protein; IS = insulinitis score; MAP = multi-analyte profile; MCP = monocyte chemoattractant protein; MDC = macrophage-derived chemokine; MIP = macrophage-inflammatory protein; MMP = matrix metalloproteinase; M3R = M3 receptor; NOD = nonobese diabetic; PANTHER = Protein ANalysis THrough Evolutionary Relationships; PCA = principal component analysis; RANTES = regulated upon activation, normal T-cell expressed and secreted; RI = ratio index; SGOT = serum glutamic-oxaloacetic transaminase; SS = Sjögren's syndrome; STAT = signal transducer and activator of transcription; Th = T-helper; VCAM = vascular cell adhesion molecule; vWF = von Willebrand factor.

late findings to existing models that were often developed in different contexts [1-3]. Recent technological advances have greatly increased the amount of information and the number of proteins that can be investigated in any given system and put into a scientific context simultaneously. These technologies, termed transcriptomics, proteomics, metabolomics and other '-omics', were followed by the an increase in systems-based thinking across different scientific disciplines [4]. This trend has promoted systems biology from a technology-driven enterprise to an innovative tool in drug discovery, and it may lead to a more complete perspective on how specific components contribute at different system levels to the immune response. Contextualization and integration have been key drivers of such approaches.

SS (for review [5,6]), a systemic autoimmune disease, is manifested by severe impairment of exocrine gland function and focal mononuclear cell infiltrates within the salivary and lacrimal glands. The identification of anti-M3 receptor (M3R) autoantibodies for the first time attributed a defined pathogenic role to an autoantibody in SS [7-9]. The roles of other autoantibodies in the pathogenesis of SS (especially SSA [anti-Ro] and SSB [anti-La], which are frequently present in patients with SS) remain to be determined. The disease can involve organs other than the exocrine glands, and the worst disease outcome – lymphoid malignancy – develops in up to 5% of patients with SS. Currently, applied treatments provide merely marginal symptomatic relief [10,11].

The nonobese diabetic (NOD) mouse, which spontaneously develops both SS-like histopathology and hyposalivation, is the most widely accepted model for SS [12,13]. Based on the findings of studies conducted in these mice [14], it is thought that the various SS-related manifestations develop according to a specific time course. However, similar to human SS, the immunological relationship between the two hallmarks of SS, namely salivary gland inflammation and hyposalivation, is far from being understood in NOD mice. Although some diabetes-related genetic loci might contribute to the SS-like disease in NOD mice, both autoimmune diseases can develop independently from each other [15]. Onset of SS in NOD mice is not critically dependent on the diabetes-related H2g7 haplotype. NOD.B10.H2b congenic mice also exhibit an SS-like disease in the absence of overt diabetes [16], which prevents exclusion of diabetic animals from studies conducted in SS. However, similar to nondiabetic parental NOD mice, they exhibit lymphoid infiltration in the pancreas and, rarely, insulinitis [17]. Another model of SS, the C57BL/6.NOD-Aec1Aec2 strain, has not been screened for SS-unrelated autoimmune manifestations other than insulinitis [15]. However, the background strain C57BL/6 develops spontaneous organ-specific autoimmune lesions in salivary glands, pancreas, kidneys, lungs and liver, and produces a variety of autoantibodies [18].

The analytes investigated in this study, which were previously studied in humans or NOD mice within the context of SS, are listed in Additional file 1 (Supplementary table 1). Few studies have assessed interactions between several immune molecules and their association with disease parameters.

Summarizing findings regarding immune mediators such as cytokines in SS, it was concluded that T-helper (Th)2 cytokines are predominant in an early phase of SS, whereas Th1 cytokines are associated with a later stage of the disease [19]. In opposition stands the proposed principle that decreased salivary flow, potentially associated with Th2 cytokines, follows the emergence of glandular inflammation, which was linked to a Th1 response [14,20]. In addition, the transition between the preclinical and the overt disease state has been associated with shifts in cytokine profiles in NOD mice [14] and the IL-4/signal transducer and activator of transcription (STAT)6 pathway [20]. Chemokines, small secreted proteins, have been implicated in leucocyte chemoattraction, angiogenesis, fibrosis and malignancy [21]. Despite their uncontested potential as targets for therapeutic intervention, few studies have examined chemokines within the context of SS (Additional file 1 [Supplementary table 1]).

The purpose of the present study was to expand knowledge regarding 87 analytes in serum and 75 proteins in saliva. Thirty and 62 of these molecules have not yet been investigated in SS patients and SS-like disease in NOD mice, respectively. Thirty-six and 54 of the biomarkers have not yet been analyzed in serum and saliva obtained from patients with SS, and neither have 70 of the analytes in serum and 62 biomarkers in saliva from NOD mice been evaluated in a SS-specific context. Based on direct comparison with Balb/c mice, we intended to identify differentially expressed proteins and investigate their potential to discriminate between the disease model and the control strain. This pool of data should also allow computation of a correlation network, representing associations of biomarkers with relevant clinical features of SS in nondiabetic NOD mice, both systemically and locally.

Materials and methods

Animals and assessment of diabetes

Twenty-two female NOD/LtJ (stock #001976) and 19 female Balb/cJ (stock #000651) mice (The Jackson Laboratory, Bar Harbor, ME, USA) were housed in individually ventilated cages at the animal facility of the Department of Physiology, University of Bergen, Bergen, Norway. The study was approved by the Committee for Research on Animals/Forsøksdyrutvalget (project #12-05/BBB).

To serve as controls for subsequent immunostimulatory intervention studies, all mice were injected subcutaneously at 7 weeks of age with 25 μ l incomplete Freund's adjuvant emulsified in phosphate-buffered saline. From 10 weeks onward NOD mice were screened weekly for diabetes. Two repeated

measurements of glucosuria (>50 mg/dl; Keto-Diabur-Test strips, Roche, Mannheim, Germany) were considered to represent onset of diabetes. At weeks 20 and 21, all mice were screened for hyperglycaemia (>300 mg/dl; Ascensia-microfill, Bayer Healthcare, Mishawaka, IN, USA). At 21 weeks, 10 out of 22 mice (45.5%) were considered to be diabetic and were excluded from all subsequent analyses. We excluded these animals in order to eliminate from our findings any SS-unrelated impact of hyperglycaemia on the physiological process of saliva secretion and the anticipated distorting effect of hyperglycaemia on biomarker profiles.

Measurement of stimulated salivary flow

Mice were fasted but given water *ad libitum* and anaesthetized with an intramuscular injection of ketamine and medetomidine. Salivary secretion was induced by intraperitoneal injection of 0.5 μ g pilocarpine/g body weight (#P6503; Sigma, St. Louis, MO, USA) and collected during 10 minutes. Pre-weighed tubes were weighed again after collection to determine the amount of saliva (1 μ g = 1 μ l). Protease inhibitor cocktail (#P8340; Sigma) was added at a concentration of 1:500 and samples were kept at -80°C until analysis.

Blood sampling and organ collection

Blood was collected from the saphenous vein from nonanaesthetized mice and by heart puncture on the day of euthanasia. The blood was allowed to clot and centrifuged for 10 minutes at 800 g to obtain serum. The organs were fixed in 4% formalin before embedding in paraffin, sectioning, and staining with haematoxylin and eosin. Sections obtained from the kidneys were also stained using the periodic acid-Schiff staining technique.

Evaluation of salivary gland inflammation and insulinitis in the pancreas

After qualitative evaluation of three independent sections, the section with the highest degree of inflammation was recorded as a whole, creating a multiple image-composite picture. A graph tablet was used to select and morphometrically measure the total glandular area and the individual size of each focus. Subsequently, focus score (FS; number of foci of 50 or more mononuclear cells/ mm^2 glandular tissue) and ratio index (RI; area of inflammation/area of glandular tissue) were determined.

To determine the insulinitis score (IS), at least five haematoxylin and eosin stained tissue sections of the pancreas were analyzed in a blinded manner. On average, 32 islets per mouse were scored, as described by Leiter [22].

Multi-analyte profiles from serum and saliva

A bead-based multiplex sandwich immunofluorescence assay was used to generate multi-analyte profiles (MAPs) from serum and saliva from the 12 nondiabetic NOD and 12 Balb/c mice, comprising 82 analytes for serum and 75 for saliva

(Additional file 1 [Supplementary table 2]). Analyses were conducted at Rules Based Medicine Inc. (Austin, TX, USA) using a fully automated system. For each multiplex, eight-point calibrators and three-level controls were included on each microtitre plate. Antibodies used in the MAP to recognize and quantify the specific autoantibodies were directed against all isotypes.

Quantification of anti-M3R antibodies

Levels of anti-M3R autoantibodies were measured as described previously [23]. In brief, aliquots of 2×10^5 Chinese hamster ovary cells, transfected with pcDNA5/FRT/V5-His MsM3R-Flp-In cells, were incubated for 1.5 hours at 4°C with 10 μ l of serum before incubation with one of the following fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse detection antibodies (purchased from Southern Biotech) diluted 1:50: isotype control, goat IgG (#0110-02); IgG (H+L; #1031-02); IgG₁ F(ab')₂ (#1072-02); IgG_{2b} F(ab')₂ (#1092-02); IgG_{2c} F(ab')₂ (#1079-02); and IgG₃ F(ab')₂ (#1102-02). The cells were analyzed using a FACSCalibur flow cytometer using Cell Quest software (BD Biosciences, San Jose, CA, USA) and FlowJo (Tree Star Inc., Ashland, OR, USA). The quantities of anti-M3R autoantibodies were analyzed by gating on the FITC-positive population situated above the threshold, set by the sample stained with the secondary antibody alone. The percentage of positive cells was calculated to represent the quantity of anti-M3R autoantibodies.

Statistical analyses

Means were compared using independent Student's *t*-test (two-tailed). Bivariate linear associations, used to generate the correlation matrixes, were computed using two-tailed Pearson correlation (*r*). Strain membership prediction was assessed by discriminant analyses (DA) and subsequent cross-validated (leave one out) group prediction. The quality of the DA function is expressed by its canonical correlation (R^*).

Principal component analyses (PCAs) were computed from MAP obtained from NOD mice with the purpose being to uncover the latent structure within protein families. Protein family membership was defined based on the Protein ANalysis THrough Evolutionary Relationships (PANTHER) classification system [24]. PCA seeks a linear combination of variables so that the maximum variance is extracted from the variables. It then removes this variance and seeks a second linear combination, and so forth. Loadings greater than 0.6 were considered defining parts of the component. For proper model specification, variables being either differentially expressed between the two strains ($P < 0.05$) and/or significantly correlated ($r > 0.6$; $P < 0.05$) with one of the disease parameters were included. As a rotation method, Varimax was chosen. The number of components was determined using the Kaiser criterion (Eigenvalue > 1.0). An explanatory criterion ($>80\%$) was applied, in addition, for growth factors and cytokines in serum. Variables being defining parts of a component were also com-

bined for DA and entered simultaneously. In serum no data were missing and in saliva missing values were excluded pairwise from all analyses except PCA and DA. All analyses were computed using SPSS 13 (SPSS Inc., Chicago, IL, USA).

Results

Autoimmune disease manifestations

At 21 weeks of age salivary secretion (expressed as $\mu\text{l}/\text{minute}$ per g bodyweight) in NOD mice ($n = 12$; 0.367 ± 0.026) was decreased by 42% compared with Balb/c mice ($n = 12$; 0.637 ± 0.024 ; $P < 0.001$; Additional file 1 [Supplementary table 2]). Salivary secretion rate classified 100% of the mice according to their strain membership, confirming the onset of overt SS in all NOD mice.

FS averaged 1.007 ± 0.087 foci/ mm^2 and RI 0.045 ± 0.007 mm^2/mm^2 in NOD, whereas Balb/c mice were free from glandular inflammation. IS in nondiabetic NOD mice averaged 0.454 ± 0.052 (Additional file 1 [Supplementary table 2]), representing mild to intermediate insulinitis expressed on a scale from 0 (no inflammation) to 1 (all islets are to a large extent invaded by lymphocytes). Importantly, among all variables only serum glutamic-oxaloacetic transaminase (SGOT; $r = -0.615$, $P = 0.033$), serum IgA ($r = -0.581$, $P = 0.048$) and anti-M3R IgG₁ ($r = 0.702$, $P = 0.011$) correlated with IS.

Histopathological evaluation of the kidneys, thyroid gland, thymus, heart, lungs, liver, stomach, small and large intestines, appendix and skin revealed a subset of NOD mice exhibiting mononuclear cell infiltration in the kidneys ($n = 5$; Additional file 1 [Supplementary figure 1A]), accompanied by hyaline casts in two cases (Additional file 1 [Supplementary figure 1B]). In one case, hyaline casts were found in the absence of lymphoid infiltration. In addition, some kidneys exhibited glomeruli with increased numbers of mesangial cells. In one kidney hyaline material was found in glomerular capillaries (Additional file 1 [Supplementary figure 1C]). Necrosis or crescent formation in the glomeruli, however, was not observed. NOD mice exhibiting signs of kidney pathology ($n = 6$) had significantly lower β_2 -microglobulin and lower anti-proteinase 3 antibody levels compared with mice free from such alterations ($n = 6$). Sections of lungs from 11 NOD mice presented foamy cells in the alveoli (Additional file 1 [Supplementary figure 1D, E]), which in three cases were accompanied by focal lymphoid infiltrates in the lungs (Additional file 1 [Supplementary figure 1D, F]). However, convincing histological patterns of interstitial lung disease were absent. Using light microscopic screening, no signs of other extraglandular disease manifestations or other independent autoimmune diseases were found.

Univariate analyses

In serum the levels of 87 biomarkers, including 14 autoantibodies and four anti-M3R antibody subclasses, were measured (Additional file 1 [Supplementary table 2]). Ten proteins,

mostly cytokines, were undetectable in serum of NOD and Balb/c. Interferon- γ was detectable in one NOD mouse and circulating fibroblast growth factor-9 in one Balb/c mouse only. In saliva 75 biomarkers were analyzed, of which IL-3 and leptin were undetectable in Balb/c mice; IL-3, leptin and glutathione S-transferase- α were detectable in only one, four and four NOD mice, respectively (Additional file 1 [Supplementary table 2]). Thirty-eight of the analytes assessed in serum were found at significantly different concentrations in NOD mice compared with Balb/c mice, whereas in saliva 34 analytes were significantly different (Table 1).

DA were subsequently computed to investigate each analyte's individual potential and relative importance in accurately predicting mouse strain. Cross-validated classification revealed 18 biomarkers in serum that predicted strain membership with 80% to 100% accuracy (hit rate) and with specificity and sensitivity up to 100%, whereas such capacity was identified for three chemokines measured in saliva (Table 2). Compared with nonvalidated group prediction, cross-validated prediction is based on all cases except the case being classified and it is thought to give a better estimate of the hit rate in the population. For each analyte shown in Table 2 the specificity (percentage of correct predictions in the NOD group) and sensitivity (percentage of correct predictions in the Balb/c group) were calculated.

Multivariate analyses

An immune response is an orchestrated process that involves several protein families and several molecules with similar molecular function. The PANTHER classification system was used to classify the analytes into families of proteins with shared function based on scientific experimental evidence and evolutionary relationships. A correlation matrix comprising the variables identified to be suitable for modelling purposes exhibited profound differences in protein associations within and among protein families (Figure 1). To gain further understanding of these interrelationships in NOD mice, PCA was computed to uncover the underlying dimensions of the immune response (Additional file 1 [Supplementary table 3]). PCA identifies patterns in data and uses a correlation matrix to find the linear combination of original variables, which accounts for most of the variance. It then represents those objects in terms of these new linear combinations, which are called principal components. The first component will be defined to account for the maximum of variation possible (Additional file 1 [Supplementary figure 3]). The second component will subsequently account for the maximum of the remaining variation, and so forth, until a certain criterion set by the researcher is met. In our dataset such patterns were clearly recognizable (Figure 1). Consequently, a large number of the original variables, entered according to protein family membership, could be combined into 27 components that still accounted for at least 80% of the original variance (Additional file 1 [Supplementary table 3]).

Table 1**Significantly different biomarker concentrations in NOD and Balb/c mice**

Serum	Fold change	<i>t</i> -test <i>P</i> value	Saliva	Fold change	<i>t</i> -test <i>P</i> value
MIP-2 (CXCL-2)	0.74	0.0130	GCP-2 (CXCL-5)	1.81	< 0.0001
IP-10 (CXCL-10)	1.70	0.0145	MIP-2 (CXCL-2)	1.83	0.0236
LTN (XCL-1)	1.40	0.0037	IP-10 (CXCL-10)	4.58	0.0001
MCP-1 (CCL-2)	1.73	0.0007	LTN (XCL-1)	2.21	0.0204
MCP-3 (CCL-7)	1.99	0.0006	MCP-1 (CCL-2)	3.95	0.0304
MIP-1 α (CCL-3)	1.37	0.0059	MCP-3 (CCL-7)	2.97	0.0024
MIP-1 γ (CCL-9)	1.43	< 0.0001	MIP-1 β (CCL-4)	3.14	0.0155
MDC (CCL-22)	1.28	0.0002	RANTES (CCL-5)	4.32	< 0.0001
MIP-3 β (CCL-19)	1.57	0.0004	Eotaxin (CCL-11)	2.80	0.0179
OPN (SPP-1)	2.32	< 0.0001	MDC (CCL-22)	2.65	0.0102
IL-10	1.17	0.0201	IL-17	2.27	0.0294
CD40L	0.61	0.0136	GM-CSF (CSF-2)	2.06	0.0377
CD40	1.59	0.0007	IL-7	2.52	0.0244
IL-1 α	0.67	0.0003	IL-10	1.36	0.0351
IL-18	1.58	0.0005	CD40	6.31	0.0277
EGF	1.44	0.0111	IL-11	12.18	0.0018
Growth hormone	3.41	0.0001	LIF	2.99	0.0116
SCF (Kitl)	1.29	0.0092	OSM	3.99	0.0102
VEGF-A	0.64	0.0051	IL-18	2.62	0.0193
Endothelin-1	1.64	0.0184	FGF-9 (ng/ml)	2.82	0.0021
Insulin	1.48	< 0.0001	M-CSF (CSF-1)	1.68	0.0289
CRP	1.85	< 0.0001	SCF (Kitl)	2.27	0.0349
Haptoglobin	1.14	0.0359	TPO	5.40	0.0003
SAP	1.43	< 0.0001	Leptin	-	0.0374
SGOT	1.33	0.0062	VCAM-1	1.49	0.0424
Factor III	1.45	0.0173	MMP-9	1.72	0.0191
Factor VII	1.54	0.0092	TIMP-1	1.58	0.0444
Fibrinogen	11.88	< 0.0001	MPO	1.97	0.0100
VCAM-1	1.39	< 0.0001	Anti-Insulin	1.32	0.0415
MMP-9	0.60	0.0170	SSB (anti-La)	1.20	0.0155
Cystatin-C	1.56	< 0.0001	Anti-RNP	1.46	0.0174
MPO	1.67	0.0001	Anti-beta 2GPI	1.56	0.0117
Apo A1	1.20	0.0024	Anti-mitochondrial	1.72	0.0392
IgA	0.47	< 0.0001	Anti-SCL70	1.40	0.0021
Anti-M3R IgG ₁	18.56	0.0029			
Anti-M3R IgG _{2b}	11.23	0.0019			
Anti-M3R IgG _{2c}	77.28	< 0.0001			
Anti-M3R IgG ₃	2.14	0.0219			

Fold change in biomarker concentrations between nonobese diabetic (NOD) and Balb/c mice. Proteins significantly different between the two strains ($P < 0.05$) are listed. For the remaining proteins, please refer to Additional file 1 (Supplementary table 2). Abbreviations not defined in the text: Apo, apolipoprotein; beta 2GPI, β_2 -glycoprotein; EGF, epidermal growth factor; FGF, fibroblast growth factor; GM-CSF, granulocyte macrophage colony-stimulating factor; Kitl, Kit ligand; LIF, leukaemia inhibitory factor; LTN, lymphotactin; M-CSF, macrophage colony-stimulating factor; MPO, myeloperoxidase; OPN, osteopontin; OSM, oncostatin M; SAP, serum amyloid P; SCF, stem cell factor; SCL, scleroderoderma; TPO, thrombopoietin; VEGF, vascular endothelial cell growth factor.

Table 2**Strain membership-prediction potential of individual biomarkers**


	R*	Specificity	Sensitivity	Hit rate
Salivary flow	0.849	100%	100%	100%
Serum				
IgA	0.921	100%	100%	100%
Anti-M3R IgG _{2c}	0.902	92%	100%	96%
Cystatin-C	0.856	83%	92%	88%
Insulin	0.837	92%	83%	88%
CRP	0.812	92%	92%	92%
MIP-1 γ (CCL-9)	0.784	100%	92%	96%
VCAM-1	0.783	92%	92%	92%
OPN (SSP-1)	0.778	83%	92%	88%
SAP	0.757	92%	83%	88%
Fibrinogen	0.747	83%	100%	92%
MPO	0.708	75%	92%	83%
Growth hormone	0.703	67%	100%	83%
MDC (CCL-22)	0.693	75%	92%	83%
IL-1 α	0.678	83%	83%	83%
MIP-3 β (CCL-19)	0.665	92%	92%	92%
IL-18	0.653	75%	100%	88%
MCP-3 (CCL-7)	0.648	67%	92%	79%
CD40	0.645	67%	92%	79%
MCP-1 (CCL-2)	0.643	67%	100%	83%
Anti-M3R IgG _{2b}	0.600	67%	100%	83%
Saliva				
RANTES (CCL-5)	0.799	75%	92%	83%
GCP-2 (CXCL-5)	0.745	75%	92%	83%
IP-10 (CXCL-10)	0.731	75%	100%	88%
TPO	0.678	67%	83%	75%
Anti-SCL70	0.645	50%	100%	80%
IL-11	0.603	58%	92%	75%

Results from uni-variate DA sorted according to their canonical correlation. Only predictors yielding a canonical correlation >0.6 were included. Specificity (percentage of correct predictions in the NOD group), sensitivity (percentage of correct predictions in the Balb/c group) and hit ratio (% of correctly classified cases) represent results obtained from cross-validated (leave-one-out) group prediction analyses. CRP, C-reactive protein; MPO, myeloperoxidase; OPN, osteopontin; SAP, serum amyloid P; TPO, thrombopoietin.

Subsequently, linear interrelationships were analyzed using Pearson correlation. The extraction of principal components reduced the correlation matrix considerably, from 9'604 (Figure 1) to 1'994 coefficients (Figure 2). Components associated with disease manifestations are presented in Figures 2 and 3, whereas correlations between components are shown in Figures 2 and 4. Variables for which no reasonable component structure could be computed were included as


original variables, if a significant correlation with an autoimmune manifestation was detected (Figures 2 and 3). Results from multivariate DA, based on the simultaneous entry of the variables combined in the different components, are listed in Additional file 1 (Supplementary table 4). They represent the relative importance of the collinear variables, combined in an individual component, in predicting strain membership.

Figure 1



Correlation matrix from original variables measured in NOD and Balb/c mice. Correlation matrix of proteins differently expressed ($P < 0.05$) between nonobese diabetic (NOD) and Balb/c mice or significantly associated with autoimmune manifestations in NOD ($r > 0.6$, $P < 0.05$) sorted according to protein family membership and principal component structure. The lower left triangle displays the coefficients obtained from NOD, and the upper right triangle the values obtained from Balb/c mice. Red indicates positive correlation, and green negative correlation. Colour saturation indicates the strength of the association. Protein names printed in black are variables that could not be fitted in principal component analyses. Red lettering identifies the variable as being a significant part of component 1, blue of component 2, green of component 3, and so on, of the corresponding of protein family. *Variables representing measurements in saliva. The figure was drawn using iVici 0.91. Abbreviations not defined in the text: Apo, apolipoprotein; beta 2GPI, β_2 -glycoprotein; CRP, C-reactive protein; EGF, epidermal growth factor; FGF, fibroblast growth factor; GM-CSF, granulocyte macrophage colony-stimulating factor; GRO, melanoma growth stimulatory activity protein; LIF, leukaemia inhibitory factor; LTN, lymphotactin; M-CSF, macrophage-colony stimulating factor; MPO, myeloperoxidase; OPN, osteopontin; OSM, oncostatin M; SAP, serum amyloid P; SCF, stem cell factor; SCL, scleroderma; TIMP, tissue inhibitor of metalloproteinase; TPO, thrombopoietin; VEGF, vascular endothelial cell growth factor.

Figure 2




Correlation matrix of principal components and original variables associated with autoimmune manifestations. Correlation matrix of principal components and original variables sorted according to their associations with Sjögren's syndrome (SS) disease manifestations. The upper right triangle indicates significant *P* values with yellow fill (*P* < 0.05). The lower left triangle displays the corresponding *r*. Red indicates positive correlation and green negative correlation, and colour saturation indicates the strength of the association. Abbreviations not defined in the text: CRP, C-reactive protein; SAP, serum amyloid P.

Salivary flow

Correlation analyses indicated no linear association between salivary flow and the parameters of glandular inflammation (Figure 2 and 3). PCA identified three components in serum (Se-C) and two in saliva (Sa-C) that correlated with salivary

flow (Figure 3). The defining variables of the components are specified in parentheses. Chemokine Se-C-2 (macrophage-inflammatory protein [MIP]-1 α , MIP-1 γ and monocyte chemoattractant protein [MCP]-5), cytokine Se-C-4 (IL-10) and growth factor Se-C-2 (macrophage-colony stimulating factor

Figure 3



Schematic map of principal component associations. Model of principal component associations and selected original variables with autoimmune manifestations. Red arrows mark significant positive correlations and green arrows significant negative correlations. Orange arrows represent significant associations of components with significant positive and negative loadings. The defining variables of the components are given in parentheses. Dotted lines and grey lettering mark borderline significance. The associations involving circulating serum amyloid P (SAP), endothelin-1 and insulin are not shown in the figure; please refer to Figure 2. Abbreviations not defined in the text: beta 2GPI, β_2 -glycoprotein; CRP, C-reactive protein; EGF, epidermal growth factor; FGF, fibroblast growth factor; GM-CSF, granulocyte macrophage colony-stimulating factor; GRO, melanoma growth stimulatory activity protein; IFN, interferon; LIF, leukaemia inhibitory factor; LTN, lymphotactin; M-CSF, macrophage-colony stimulating factor; OSM, oncostatin M; SCF, stem cell factor; SCL, scleroderoderma; TPO, thrombopoietin; VEGF, vascular endothelial cell growth factor.

and growth hormone) were all positively correlated with salivary flow (Figure 3 and Additional file 1 [Supplementary table 3]). The same applied for the following serum analytes, for which no PCA-based solution could be computed: C-reactive protein, SGOT, vascular cell adhesion molecule (VCAM)-1 and IgA.


In saliva, C-C chemokine ligand/C chemokine ligand Sa-C-2 (eotaxin and macrophage-derived chemokine [MDC]) and cytokine Sa-C-3 (CD40 and CD40L [IL-18 borderline]) correlated with decreased salivary flow. Not reflected by their corresponding component, salivary IL-5 ($r = -0.708$, $P = 0.010$), thrombopoietin ($r = -0.766$, $P = 0.004$) and factor III ($r = -0.614$, $P = 0.034$) also correlated with salivary flow.

Glandular inflammation

Glandular inflammation was negatively correlated with cytokine Se-C-2 (negative loading for IL-1 α [-0.94] and positive loading for CD40 ligand [CD40L; 0.68]). Interestingly, this component was correlated with SSB in serum.

In saliva multiple factors exhibited a linear interrelationship with measures of glandular inflammation. Acute phase reactants Sa-C-1 (C-reactive protein, SGOT and serum amyloid P) and coagulation factor Sa-C-2 (von Willebrand factor [vWF] and fibrinogen) correlated negatively with FS and RI. vWF was negatively loaded on coagulation factor Sa-C-2, consistent with its initial positive correlation with increased IR ($r = 0.792$, $P = 0.002$). In addition, secretory IgA was inversely correlated with FS. Components extracted from protein families involved in specific immune reactions revealed C-X-C chemokine ligand (CXCL) Sa-C-2 (granulocyte chemotactic protein [GCP]-2) to be positively correlated with IR ($r = 0.664$, $P = 0.018$), and cytokine Sa-C-1, combining eight cytokines, exhibited a negative association with IR. In contrast, cytokine Sa-C-2 (leukaemia inhibitory factor, IL-10 and IL-1 β) showed an almost significant positive correlation with FS and IR (both $r = 0.581$, $P = 0.061$). Correlation patterns compared with other components further supports its connection with glandular inflammation (Figure 2).

Figure 4



Schematic map of principal component associations. Model of bidirectional inter-component associations. Red arrows mark significant positive correlations and green arrows significant negative correlations. Orange arrows represent interrelations of components of which at least one had significant positive and negative loadings.

Autoantibodies

We found all isotypes of M3R autoantibodies that we investigated to be significantly increased in NOD mice compared with Balb/c mice. Circulating SSB was the only autoantibody that significantly correlated with any SS disease manifestation. PCA failed to extract components from circulating autoantibody levels, and therefore individual associations are reported in Figures 2 and 3. Interestingly, SSB levels were associated with cytokine Se-C-2 ($r = -0.590, P = 0.043$) and VCAM-1 ($r = 0.587, P = 0.045$) and anti-M3R IgG₁ correlated with cytokine Se-C-5 (IL-18; $r = 0.649, P = 0.023$). Levels of anti-M3R IgG₃ correlated negatively with MIP-1 α ($r = -0.626, P = 0.029$) and MCP-5 ($r = -0.580, P = 0.048$), which in turn were associated with salivary flow ($r = 0.735, P = 0.006$ and $r = 0.742, P = 0.006$, respectively). Consistent with this observation, levels of anti-M3R IgG₃ correlated with cytokine Sa-C-3 (CD40, CD40L and borderline IL-18; $r = 0.724, P = 0.012$) on its part associated with decreased salivary flow. In addition, the positive association between M3R IgG₃ and CXCL Sa-C-2 (GCP-2; $r = 0.789, P = 0.002$) in its turn correlating with RI, suggests that anti-M3R IgG₃ has a role in connecting different SS-related disease manifestations. In addition, salivary matrix metalloproteinase (MMP)-9 also correlated positively with increased anti-M3R IgG₃.

Autoantibodies in saliva were grouped into autoantibody Sa-C-1 (anti-RNP, anti-insulin, anti-mitochondrial, SSB and anti-scleroderma-70 antibodies) and autoantibody Sa-C-2 (anti- β_2 glycoprotein). Components positively correlated with autoanti-

body Sa-C-1 were chemokine Se-C-3 (MIP-3 β , lymphotactin and MDC), C-C chemokine ligand/XCL Sa-C-1 (lymphotactin, MCP-3, MIP-1 β , MCP-1 and RANTES [regulated upon activation, normal T-cell expressed and secreted]), CXCL Sa-C-1 (melanoma growth stimulatory-activity protein, MIP-2, inducible protein [IP]-10 and GCP-2) and growth factor Sa-C-1 (stem-cell factor, fibroblast growth factor-9 and thrombopoietin). In contrast, chemokine Se-C-2 and cytokine Se-C-4, in turn also associated with salivary flow, exhibited a significant negative correlation with autoantibody Sa-C-1. Growth factor Se-C-3 (epidermal growth factor) and coagulation factor Se-C-1 (factors VII and III), together with endothelin-1, correlated negatively with autoantibody Sa-C-1 as well. Autoantibody Sa-C-2 correlated positively with chemokine Se-C-1 (MCP-1, MCP-3, MIP-2 and IP-10) and circulating insulin.

In summary, proteins were mostly associated exclusively with either salivary flow, parameters of glandular inflammation, or autoantibody levels. Dual associations were only apparent for the following: chemokine Se-C-2, cytokine Se-C-4, cytokine Se-C-2, cytokine Sa-C-3 and CXCL Sa-C-2. From variables not included in PCA, only VCAM-1 in serum correlated with two autoimmune parameters.

Associations among components

Correlations among components associated with autoimmune manifestations are presented in Figures 2 and 4. Between components associated with salivary flow, an antagonistic interplay between cytokine Sa-C-3 (associated with

decreased salivary flow) and all three components extracted from serum (positively associated with salivary flow) was apparent. Components associated with FS and/or RI correlated strongly with each other, indicating a process in which cytokine Sa-C-2 and CXCL Sa-C-2 oppose acute-phase reactant Sa-C-1 and secreted IgA. In addition, cytokine Se-C-2 and coagulation factor Sa-C-2 played a dual role by combining the positively associated IL-1 α and vWF with the negatively associated CD40L and fibrinogen, respectively. Regarding components associated with autoantibodies, the components related to anti-M3R IgG₁ correlated negatively with autoantibody Sa-C-1, whereas all components that were positively associated with autoantibody Sa-C-1 correlated with each other.

We observed a complete absence of original variables or components that correlated with salivary flow and either FS or RI. This absence was as absolute when analyzing inter-component correlations (Figure 2). In contrast, some components were associated with either salivary flow or glandular inflammation, having positive or negative inter-relationships with components related to autoantibody levels, such as cytokine Se-C-4 (IL-10) and cytokine Sa-C-1 (interferon- γ , IL-7, oncostatin M, granulocyte macrophage-colony stimulating factor, IL-17, IL-11, IL-5 and IL-18). CXCL Sa-C-2 (GCP-2) exhibited negative associations with the proteins related to increased anti-M3R IgG₁ and positive associations with anti-M3R IgG₃ and MMP-9. Interestingly, MMP-9 expression correlated positively with components associated with increased glandular inflammation.

Discussion

By studying the immune system through the application of reductionist principles, its mediators have been thoroughly analyzed over recent decades, which has yielded tremendous scientific advances. However, studying the properties of its isolated components is limited in terms of elucidating how system properties emerge, because they may strongly rely on and arise from interactions between its numerous constituents. In this study we present a substantial amount of data on immunologically relevant proteins, for which often only scant or no information within the context with SS has been published. Multiplexing of analytes thus significantly diminished the sample volume required and enabled us to investigate the analytes' connectivity through correlation networks. Such a study cannot be as conclusive in defining the role of a single protein as a component-focused experimental study design. However, it represents a novel way to analyze the implications of multiple molecules in a specific condition, by providing insight into the inter-relationships that define a specific system state.

Analyses of protein levels instead of mRNA expression data can allow exclusion of certain factors that cause uncertainty, such as RNA stability and correlations between mRNA levels and corresponding protein levels. A recent study combined

global gene expression analyses with quantitative proteomics based on two-dimensional gel electrophoresis and mass spectrometry in saliva obtained from patients with SS [25]. Indeed, the correlation between mRNA levels and proteins was proven to be poor. Using mass spectrometry, 42 proteins were identified that were significantly altered when comparing pooled saliva from SS patients with healthy control individuals [25]. None of the proteins identified by Hu and coworkers [25] was included in our MAP. Two-dimensional gel electrophoresis is limited in terms of its sensitivity in identifying proteins with concentrations in the pg/ml range, especially if they may be masked by abundant proteins present in the biofluid of interest. However, methods such as stable-isotope protein tagging or subtractive proteomics may improve the number of immune system related proteins identified by mass spectrometry. Nevertheless, the two approaches of antibody-based biomarker identification and mass spectrometry-based global proteome profiling may well complement one another in delineating SS-specific disease signatures. Nevertheless, further technological advances are required in both fields to achieve more complete coverage of crucial immune mediators. Unfortunately, molecules of proven importance in SS, such as B-cell activating factor [26] and type I interferons [27] were not part of our MAP. Including such crucial molecules in future studies and the present correlation network would indeed greatly increase completeness and enhance the plausibility of an integrated model of SS.

By accounting for SS-related extraglandular autoimmune manifestations and insulinitis, we are confident that analyses in serum reflect to a large extent systemic aspects of SS. Nevertheless, although we could not associate the presence of extraglandular disease manifestations with the situation in the salivary glands, it would be of interest to investigate further the involvement of kidneys and lungs in both experimental and human SS [28-30]. The potential presence of SS-unrelated histopathology or of other subclinical autoimmune diseases in mouse models for SS represents a common problem of all mouse models used in SS research [13,31]. This divergence of these models from clinical SS may lead one to draw erroneous conclusions from measurements in serum. Indeed, biomarker profiling solely focusing on serum or plasma may require considerable validation efforts to prove their specificity for a specific autoimmune disease such as SS.

In contrast, because it is directly collected from the site of inflammation, saliva may largely reflect the immunological situation in the salivary glands. The presence and local production of some inflammatory mediators and autoantibodies in the salivary glands were previously described (Additional file 1 [Supplementary table 1]); these findings were largely confirmed by our study. Importantly, we did not observe a concentration effect related to lesser fluid secretion. In a noninflammatory situation (represented by Balb/c mice), the average correlation coefficient of analytes included in the model did not show a

negative association with salivary flow ($r = -0.076$). The noninvasive collection method and the lack of extraction procedures predispose biomarkers, measured in saliva, as potential surrogate markers of disease and disease activity [25,32]. In addition, they may reflect the disease independent from other inflammatory conditions in patients. The identification of a set of biomarkers in human saliva, similar to the three chemokines we identified in mice, that predicts the presence of glandular inflammation with high accuracy would represent a major advance in the field.

Traditionally, loss of secretory capacity, degree of lymphoid infiltration and production of specific autoantibodies have been anticipated to correlate with each other and to indicate disease state and severity [5,6]. However, the correctness of this assumption was difficult to prove. Our findings strongly argue against such close interrelationships and suggest that there is much independence of the various hallmarks of SS. Only RI and SSB correlated directly with each other, and the separation between proteins in terms of whether they were associated with hyposalivation or with glandular inflammation was absolute.

Circulating MIP-1 α and MCP-5, which we found to be associated with higher salivary flow, are Th1-related chemokines that are negatively regulated by STAT6 [33]. In opposition, eotaxin and MDC, correlating with decreased salivary flow, are dependent on STAT6 [33] and are considered to be Th2-related chemokines [34]. In accordance with these findings, STAT6-deficient NOD mice did not develop hyposalivation [20]. Both eotaxin and MDC are produced by Th2-promoting dendritic cell types upon engagement of CD40/CD40L [35]; in our study, these two proteins were associated with low salivary secretion capacity as well. CD40 and CD40L are expressed on salivary gland epithelial cells and infiltrating lymphocytes in biopsies obtained from SS patients [36]. The observed correlation between CD40/CD40L and anti-M3R IgG₃ levels may therefore be related to the primary role played by CD40 and CD40L in B-cell survival, B-cell proliferation, antibody production and antibody isotype switching [37]. We found all of the antibody isotypes binding M3R that we measured to be upregulated, with (perhaps most importantly) positive associations between M3R IgG₃ and secretory CD40, CD40L, IL-18, GCP-2 and MMP-9. Previous studies identified IgG₁ as the crucial isotype in anti-M3R antibody mediated inhibition of salivary flow in STAT6^{-/-} [20] and IL4^{-/-} [23] deficient NOD mice. Nevertheless, IgG₂ subclasses and IgG₃ are generally considered to be significantly more potent in mediating pathogenic effects [38]. In contrast to other isotypes, the effect of IgG₃ is FcR independent and strictly related to complement activation; the latter component of the immune system was recently related to SS pathology [39]. In addition, IgG₃ can form complexes through self-association and generate cryoglobulins [38], a feature observed in SS [6]. With regard to the quality of the antibody response, we found total

circulating and secretory IgA to be related to lower disease activity.

Apart from B-cell fate, CD40/CD40L ligation plays a central role in converting a tolerogenic antigen presentation into pathogenic immune activation [40]. In conditions with chronic inflammation, CD40 and other inflammatory mediators can have adverse effects on tissue renewal and repair processes [41]. Indeed, we found specific growth factors to be negatively correlated with CD40 and CD40L and secreted autoantibodies. Furthermore, we found circulating IL-10 to correlate negatively with CD40/CD40L; the anti-inflammatory properties of IL-10 may apply to our model, because increased circulating IL-10 did correlate with higher salivary flow and lower autoantibody concentrations in saliva. IL-10 gene transfer in NOD mice partially suppressed the appearance of SS-like features [42]. However, we found IL-10 in saliva to be associated with glandular inflammation, which corroborates reports indicating that IL-10 transgenic mice develop progressive histopathology and hyposalivation, evocative of SS [43].

With the exception of vWF, increased concentrations of proteins in saliva related to acute tissue injury were all associated with a lower degree of glandular inflammation. These events may be followed later by inflammatory cell invasion into the glandular tissue and/or mirror an imbalance between processes that restore homeostasis and factors that promote chronic inflammation. Higher levels of IL-1 family members did correlate with both worsening of hyposalivation and increased glandular inflammation. IL-1 β is also a major inducer of GCP-2 [44] and was, similar to IL-1 β , associated with glandular inflammation. Leukaemia inhibitory factor, inducible through IL-1 β [45] and loaded on the same component together with IL-1 β and IL-10, has been shown to have parallels with IL-1, tumour necrosis factor- α and IL-6 within the context of promoting inflammation in rheumatoid arthritis [45].

Among the biomarkers analyzed in saliva, GCP-2, IP-10 and RANTES exhibited the greatest potential in predicting strain membership. GCP-2 is expressed at neutrophil and macrophage dominated inflammatory sites, IP-10 is related to Th1 immune responses, and RANTES can be involved in Th1 and Th2 immune responses [46]. GCP-2 and IP-10 have opposite roles in angiogenesis [47]; this issue has not yet been addressed in SS, despite the recognized importance of neovascularization in promoting the influx of inflammatory cells [48]. Proteins such as GCP-2, vascular endothelial growth factor, epidermal growth factor, IL-1, VCAM-1 and MMP-9, which we found to be significantly increased in NOD mice, are involved in angiogenesis [48]. In addition, angiostatic molecules such as IP-10, tissue inhibitor of metalloproteinase-1 and endostatin-1 were also altered [48]. Based on our findings, pathogenic neovascularization deserves to receive more attention in SS research.

Conclusion

Increased concentrations of molecules that govern adaptive immune responses were associated with an aggravation of SS coupled with a strong association of Th2-related proteins with hyposalivation. In addition, we observed great independence among the different disease manifestations of SS, which must be considered when one is evaluating potential drug targets. Nevertheless, CD40, CD40L, IL-18, GCP-2 and anti-M3R IgG₃ may, however, represent a pivotal point that intersects the various aspects of SS pathology. As multiplex technology allowed us to draw a comprehensive picture of the overt disease stage, we suggest that treatment outcome may similarly be monitored [49]. Hypothesis-driven verification of our findings, together with validation of our findings in human SS specimens, are important goals for the future. We also believe that discovery-driven studies, such as the one presented here, can widen the horizon and inspire new component-focused basic research. Nevertheless, bridging the gap between these two approaches represents a major challenge for the years to come, but the reward will be a more integrated perspective on immunology and autoimmune disease.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

ND and RJ designed the study. ND carried out the animal experiments, salivary flow measurements and collection of organs. HI participated in preparation and carried out the qualitative evaluation of the organs. ND carried out the morphometrical analyses. JC and ND carried out the fluorescence-activated cell sorting analyses for anti-M3R autoantibodies. ND carried out the data analyses. ND and RJ wrote the manuscript. RJ supervised the study. All authors read and approved the final manuscript.

Additional files

The following Additional files are available online:

Additional file 1

Supplementary table 1 provides a literature overview; Supplementary table 2 provides a comparison of disease parameters and analyte concentrations in serum and saliva; Supplementary table 3 provides principal component analyses (component structure and loadings); Supplementary table 4 shows strain membership prediction by defining variables from principal components; and Supplementary figure 1 shows extraglandular disease manifestations in the kidneys and the lungs present in a subset of NOD mice. See <http://www.biomedcentral.com/content/supplementary/ar2375-S1.pdf>

Acknowledgements

Funding for this study was provided by The Meltzer Fond, Olaf and Gullborg Johannessens Legacy, the Broegelmann Foundation and the Strategic Research Program, and Western Norway Regional Health Authority. We thank Ana Carina Madureira, Gry Bernes and the staff at the Animal Facility, Department of Physiology, University of Bergen and at the Department of Pathology, Haukeland University Hospital, Bergen, Norway for excellent technical assistance. In addition, we thank Inge Jonassen from the Bergen Center of Computational Biology for helpful advice, Dr B Delaleu-Justitz for careful revision of the manuscript, and Dr S Küster for her support.

References

- Zinkernagel RM, Hengartner H: **On immunity against infections and vaccines: credo 2004**. *Scand J Immunol* 2004, **60**:9-13.
- Anderson CC: **Time, space and contextual models of the immunity tolerance decision: bridging the geographical divide of Zinkernagel and Hengartner's 'Credo 2004'**. *Scand J Immunol* 2006, **63**:249-256.
- Cohn M: **A commentary on the Zinkernagel-Hengartner 'Credo 2004'**. *Scand J Immunol* 2005, **62**:187-194.
- van der Greef J, Martin S, Juhasz P, Adourian A, Plasterer T, Verheij ER, McBurney RN: **The art and practice of systems biology in medicine: mapping patterns of relationships**. *J Proteome Res* 2007, **6**:1540-1559.
- Delaleu N, Jonsson R, Koller MM: **Sjögren's syndrome**. *Eur J Oral Sci* 2005, **113**:101-113.
- Jonsson R, Bowman SJ, Gordon T: **Sjögren's Syndrome**. In *Arthritis and Allied Conditions: A Textbook in Rheumatology Volume 2*. 15th edition. Edited by: Koopman W. Philadelphia, PA: Lippencott William & Wilkins; 2005:1681-1706.
- Robinson CP, Brayer J, Yamachika S, Esch TR, Peck AB, Stewart CA, Peen E, Jonsson R, Humphreys-Beher MG: **Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjögren's syndrome**. *Proc Natl Acad Sci USA* 1998, **95**:7538-7543.
- Dawson LJ, Stanbury J, Venn N, Hasdimir B, Rogers SN, Smith PM: **Antimuscarinic antibodies in primary Sjögren's syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cells**. *Arthritis Rheum* 2006, **54**:1165-1173.
- Gao J, Cha S, Jonsson R, Opalko J, Peck AB: **Detection of anti-type 3 muscarinic acetylcholine receptor autoantibodies in the sera of Sjögren's syndrome patients by use of a transfected cell line assay**. *Arthritis Rheum* 2004, **50**:2615-2621.
- Delaleu N, Jonsson MV, Jonsson R: **Disease mechanisms of Sjögren's syndrome**. *Drug Discovery Today* 2004, **1**:329-336.
- Fox RI: **Sjögren's syndrome**. *Lancet* 2005, **366**:321-331.
- Cha S, Peck AB, Humphreys-Beher MG: **Progress in understanding autoimmune exocrinopathy using the non-obese diabetic mouse: an update**. *Crit Rev Oral Biol Med* 2002, **13**:5-16.
- Jonsson MV, Delaleu N, Jonsson R: **Animal models of Sjögren's syndrome**. *Clin Rev Allergy Immunol* 2007, **32**:215-224.
- Jonsson MV, Delaleu N, Brokstad KA, Berggreen E, Skarstein K: **Impaired salivary gland function in NOD mice: association with changes in cytokine profile but not with histopathologic changes in the salivary gland**. *Arthritis Rheum* 2006, **54**:2300-2305.
- Cha S, Nagashima H, Brown VB, Peck AB, Humphreys-Beher MG: **Two NOD Idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sjögren's syndrome) on a healthy murine background**. *Arthritis Rheum* 2002, **46**:1390-1398.
- Robinson CP, Yamachika S, Bounous DI, Brayer J, Jonsson R, Holmdahl R, Peck AB, Humphreys-Beher MG: **A novel NOD-derived murine model of primary Sjögren's syndrome**. *Arthritis Rheum* 1998, **41**:150-156.
- Wicker LS, Appel MC, Dotta F, Pressey A, Miller BJ, DeLarato NH, Fischer PA, Boltz RC Jr, Peterson LB: **Autoimmune syndromes in major histocompatibility complex (MHC) congenic strains of nonobese diabetic (NOD) mice. The NOD MHC is dominant for**

- insulinitis and cyclophosphamide-induced diabetes. *J Exp Med* 1992, **176**:67-77.
18. Hayashi Y, Utsuyama M, Kurashima C, Hirokawa K: **Spontaneous development of organ-specific autoimmune lesions in aged C57BL/6 mice.** *Clin Exp Immunol* 1989, **78**:120-126.
 19. Mitsias DI, Tzioufas AG, Veiopoulou C, Zintzaras E, Tassios IK, Kogopoulou O, Moutsopoulos HM, Thyphronitis G: **The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjögren's syndrome.** *Clin Exp Immunol* 2002, **128**:562-568.
 20. Nguyen CQ, Gao JH, Kim H, Saban DR, Cornelius JG, Peck AB: **IL-4-STAT6 signal transduction-dependent induction of the clinical phase of Sjögren's syndrome-like disease of the non-obese diabetic mouse.** *J Immunol* 2007, **179**:382-390.
 21. Mehrad B, Keane MP, Strieter RM: **Chemokines as mediators of angiogenesis.** *Thromb Haemost* 2007, **97**:755-762.
 22. Leiter EH: **The NOD mouse: as model for insulin-dependent diabetes mellitus.** In *Current Protocols in Immunology* Edited by: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W. John Wiley and Sons, Inc. Hoboken, NJ, USA; 1997:15.19.11-15.19.23.
 23. Gao J, Killedar S, Cornelius JG, Nguyen C, Cha S, Peck AB: **Sjögren's syndrome in the NOD mouse model is an interleukin-4 time-dependent, antibody isotype-specific autoimmune disease.** *J Autoimmun* 2006, **26**:90-103.
 24. **PANTHER Classification System** [<http://www.pantherdb.org>]
 25. Hu S, Wang J, Meijer J, Jeong S, Xie Y, Yu T, Zhou H, Henry S, Vis-sink A, Pijpe J, Kallenberg C, Elashoff D, Loo JA, Wong DT: **Salivary proteomic and genomic biomarkers for primary Sjögren's syndrome.** *Arthritis Rheum* 2007, **56**:3588-3600.
 26. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, Tschopp J, Cachero TG, Batten M, Whewy J, et al.: **Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome.** *J Clin Invest* 2002, **109**:59-68.
 27. Båve U, Nordmark G, Lövgren T, Ronnelid J, Cajander S, Eloranta ML, Alm GV, Rönnblom L: **Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism.** *Arthritis Rheum* 2005, **52**:1185-1195.
 28. Parambil JG, Myers JL, Lindell RM, Matteson EL, Ryu JH: **Interstitial lung disease in primary Sjögren syndrome.** *Chest* 2006, **130**:1489-1495.
 29. Tu WH, Shearn MA, Lee JC, Hopper J Jr: **Interstitial nephritis in Sjögren's syndrome.** *Ann Intern Med* 1968, **69**:1163-1170.
 30. Moutsopoulos HM, Balow JE, Lawley TJ, Stahl NI, Antonovych TT, Chused TM: **Immune complex glomerulonephritis in sicca syndrome.** *Am J Med* 1978, **64**:955-960.
 31. Hjelmervik TO, Lindqvist AK, Petersen K, Johannesson M, Stavrum AK, Johansson A, Jonsson R, Holmdahl R, Bolstad AI: **The influence of the NOD Nss1/Idd5 loci on sialadenitis and gene expression in salivary glands of congenic mice.** *Arthritis Res Ther* 2007, **9**:R99.
 32. Larsen MR, Jensen SS, Jakobsen LA, Heegaard NH: **Exploring the sialome using titanium dioxide chromatography and mass spectrometry.** *Mol Cell Proteomics* 2007, **6**:1778-1787.
 33. Fulkerson PC, Zimmermann N, Hassman LM, Finkelman FD, Rothenberg ME: **Pulmonary chemokine expression is coordinately regulated by STAT1, STAT6, and IFN-gamma.** *J Immunol* 2004, **173**:7565-7574.
 34. Lloyd CM, Delaney T, Nguyen T, Tian J, Martinez AC, Coyle AJ, Gutierrez-Ramos JC: **CC chemokine receptor (CCR)3/eotaxin is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo.** *J Exp Med* 2000, **191**:265-274.
 35. Lebre MC, Burwell T, Vieira PL, Lora J, Coyle AJ, Kapsenberg ML, Clausen BE, De Jong EC: **Differential expression of inflammatory chemokines by Th1- and Th2-cell promoting dendritic cells: a role for different mature dendritic cell populations in attracting appropriate effector cells to peripheral sites of inflammation.** *Immunol Cell Biol* 2005, **83**:525-535.
 36. Dimitriou ID, Kapsogeorgou EK, Moutsopoulos HM, Manoussakis MN: **CD40 on salivary gland epithelial cells: high constitutive expression by cultured cells from Sjögren's syndrome patients indicating their intrinsic activation.** *Clin Exp Immunol* 2002, **127**:386-392.
 37. Clark LB, Foy TM, Noelle RJ: **CD40 and its ligand.** *Adv Immunol* 1996, **63**:43-78.
 38. Baudino L, Azeredo da Silveira S, Nakata M, Izui S: **Molecular and cellular basis for pathogenicity of autoantibodies: lessons from murine monoclonal autoantibodies.** *Springer Semin Immunopathol* 2006, **28**:175-184.
 39. Nguyen CQ, Kim H, Cornelius JG, Peck AB: **Development of Sjögren's syndrome in nonobese diabetic-derived autoimmune-prone C57BL/6.NOD-Aec1Aec2 mice is dependent on complement component-3.** *J Immunol* 2007, **179**:2318-2329.
 40. Quezada SA, Bennett K, Blazar BR, Rudensky AY, Sakaguchi S, Noelle RJ: **Analysis of the underlying cellular mechanisms of anti-CD154-induced graft tolerance: the interplay of clonal energy and immune regulation.** *J Immunol* 2005, **175**:771-779.
 41. Peguet-Navarro J, Dalbiez-Gauthier C, Moulon C, Berthier O, Reano A, Gaucherand M, Banchereau J, Rousset F, Schmitt D: **CD40 ligation of human keratinocytes inhibits their proliferation and induces their differentiation.** *J Immunol* 1997, **158**:144-152.
 42. Kok MR, Yamano S, Lodde BM, Wang J, Couwenhoven RI, Yakar S, Voutetakis A, Leroith D, Schmidt M, Afione S, et al.: **Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjögren's syndrome.** *Hum Gene Ther* 2003, **14**:1605-1618.
 43. Saito I, Haruta K, Shimuta M, Inoue H, Sakurai H, Yamada K, Ishimaru N, Higashiyama H, Sumida T, Ishida H, et al.: **Fas ligand-mediated exocrinopathy resembling Sjögren's syndrome in mice transgenic for IL-10.** *J Immunol* 1999, **162**:2488-2494.
 44. Zachlederova M, Jarolim P: **Gene expression profiles of microvascular endothelial cells after stimuli implicated in the pathogenesis of vasooclusion.** *Blood Cells Mol Dis* 2003, **30**:70-81.
 45. Okamoto H, Yamamura M, Morita Y, Harada S, Makino H, Ota Z: **The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis.** *Arthritis Rheum* 1997, **40**:1096-1105.
 46. Olson TS, Ley K: **Chemokines and chemokine receptors in leukocyte trafficking.** *Am J Physiol Regul Integr Comp Physiol* 2002, **283**:R7-R28.
 47. Strieter RM, Gomperts BN, Keane MP: **The role of CXC chemokines in pulmonary fibrosis.** *J Clin Invest* 2007, **117**:549-556.
 48. Bodolay E, Koch AE, Kim J, Szegedi G, Szekanecz Z: **Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases.** *J Cell Mol Med* 2002, **6**:357-376.
 49. Delaleu N, Madureira AC, Immervoll H, Jonsson R: **Inhibition of experimental Sjögren's syndrome through immunization with heat-shock protein 60 kDa and its peptide aa437-460.** *Arthritis Rheum* in press.

Supplementary table 1) Literature overview

	Human material			NOD and SS		
	Serum	Saliva	Other	Serum	Saliva	Other
IP-10 (CXCL-10)						[1]
LTN (XCL-1)						[1]
MCP-1 (CCL-2)	[2, 3]					
MIP-1 α (CCL-3)	[2, 3]		[4]			
MIP-1 β (CCL-4)	[2, 3]		[4]			
RANTES (CCL-5)	[2, 3]		[4]			[1, 5]
Eotaxin (CCL-11)	[2, 3]					
IFN- γ	[2, 3]	[6, 7]	[7-10]	[11]	[11]	[5, 12, 13]
IL-12p70	[2, 3]		[8, 10]	[11]	[11]	[5, 13]
IL-4	[2, 3]	[7]	[7, 8, 10]	[11, 13]	[11]	[5, 14]
IL-5	[2, 3]	[7]	[7]	[11]	[11]	
IL-17	[2, 3]					
GM-CSF (CSF-2)	[2, 3]		[9]	[11]	[11]	
IL-2	[2, 3]	[7]	[7-10]	[11, 13]	[11]	[5]
IL-10	[2, 3]	[7]	[7, 8]	[11, 13]	[11]	[5, 15]
TNF- α	[2, 3]	[7]	[7, 8]	[11]	[11]	[5]
CD40L	[16]	[16]				
CD40			[17]			
IL-1 α	[2]	[7]	[7]			[13]
IL-1 β			[8, 9]	[11]	[11]	
IL-18	[18, 19]		[10, 19]			
IL-6	[2, 3]	[6, 7]	[7-9]	[11, 13]	[11]	[5]
EGF	[3]		[20]		[21]	[12]
FGF-b (FGF-2)	[22]	[22]				
Growth Hormone	[23]		[23]			
VEGF-A	[3]					
CRP	[24, 25]					
Haptoglobin	[26]					
SGOT		[27]				
Fibrinogen	[25]		[28]			
vWF	[29]					
VCAM-1	[30]	[30]	[31]			[32]
MMP-9	[33, 34]	[35]	[33, 36]		[37]	[37, 38]
TIMP-1	[34]	[35]	[36]			
Cystatin-C		[39]				
MPO	[40]					
NGAL	[40]		[41]			
Apo-A1	[42, 43]					
B ₂ m	[44]	[39]	[45]			
Clusterin		[30]	[30]			
GST-Mu			[46]			
IgA	[47]	[48]	[49]		[50]	
anti-M3R	[51, 52]		[53]	[13]		
SSA (anti-Ro)	[54]	[55]	[56]	[57]		
SSB (anti-La)	[54]	[55]	[56]	[57]		
anti-RNP	[54, 58]					
anti-pCNA	[59]					
anti-Proteinase 3	[60]					
anti-Sm	[54, 58]					
anti-beta 2GPI	[61]					
anti-MPO	[60, 62]	[62]				
anti-Jo1	[58]					
anti-Mitochondrial	[63]					
anti-SCL70	[54, 58]					
anti-Ribosomal P	[64]					

Molecules included in this study analyzed previously in either, specimens obtained from patients with SS or reported in relation with SS-like pathology in NOD mice. The column “other” includes IHC on tissue sections, *in-situ* hybridization, RNA extracts etc. The search was limited to publications written in English and indexed in PubMed. The most common synonyms and MeSH terms were included in the search, which was finalized in June 2007. Abbreviations not introduced in the main manuscript: B2m (beta-2 microglobulin), GST (glutathione S-transferase), Jo-1 (histidyl-RNA synthetase), NGAL (lipocalin-2), pCNA (proliferating cell nuclear antigen), Sm (Smith), RNP (ribonuclear protein), TNF (tumor necrosis factor).

Supplementary table 2) Comparison of disease parameters and analyte concentrations in serum and saliva

Pathology	Strain					t-test (sig. 2-tailed)	Strain					t-test (sig. 2-tailed)
	Balb/c		NOD		Change		Balb/c		NOD		Change	
	Mean	SEM	Mean	SEM			Mean	SEM	Mean	SEM		
Salivary flow	0.64	(0.02)	0.37	(0.03)	-42%	< 0.0001						
Focus score	not present		1.01	(0.09)	-	-						
Ratio index	not present		0.05	(0.01)	-	-						
Insulinitis score	not present		0.45	(0.05)	-	-						
			Serum						Saliva			
Chemokines												
GRO (CXCL-1) [ng/ml]	n/d		n/d		-	-	0.03	(0.01)	0.08	(0.03)	+147%	0.0825
GCP-2 (CXCL-5) [ng/ml]	18.8	(0.79)	18.0	(0.82)	-4%	0.4701	0.27	(0.03)	0.49	(0.03)	+81%	< 0.0001
MIP-2 (CXCL-2) [pg/ml]	25.8	(2.30)	19.1	(0.96)	-26%	0.0130	6.44	(1.07)	11.8	(1.92)	+83%	0.0236
IP-10 (CXCL-10) [pg/ml]	41.8	(4.05)	71.3	(10.3)	+70%	0.0145	8.81	(1.93)	40.3	(5.98)	+358%	0.0001
LTN (XCL-1) [pg/ml]	80.4	(6.77)	113	(7.22)	+40%	0.0037	11.3	(2.85)	25.0	(4.66)	+121%	0.0204
MCP-1 (CCL-2) [pg/ml]	72.3	(3.49)	125	(13.0)	+73%	0.0007	1.07	(0.58)	4.22	(1.23)	+295%	0.0304
MCP-3 (CCL-7) [pg/ml]	145	(11.9)	289	(34.0)	+99%	0.0006	4.08	(1.12)	12.1	(2.06)	+197%	0.0024
MCP-5 (CCL-12) [pg/ml]	42.9	(4.97)	45.2	(8.77)	+5%	0.8255	4.70	(4.40)	3.38	(1.01)	-28%	0.7733
MIP-1 α (CCL-3) [pg/ml]	125	(13.8)	171	(5.96)	+37%	0.0059	29.0	(7.28)	37.1	(7.95)	+28%	0.4615
MIP-1 β (CCL-4) [pg/ml]	66.2	(17.4)	118	(53.2)	+79%	0.3622	17.8	(6.21)	55.8	(13.1)	+214%	0.0155
MIP-1 γ (CCL-9) [ng/ml]	9.73	(0.50)	13.9	(0.50)	+43%	< 0.0001	0.54	(0.11)	0.45	(0.05)	-17%	0.4468
RANTES (CCL-5) [pg/ml]	n/d		n/d		-	-	3.28	(0.85)	14.1	(1.52)	+332%	< 0.0001
Eotaxin (CCL-11) [pg/ml]	878	(67.2)	947	(58.5)	+8%	0.4420	1.61	(0.41)	4.50	(1.05)	+180%	0.0179
MDC (CCL-22) [pg/ml]	398	(16.6)	508	(17.7)	+28%	0.0002	7.62	(2.44)	20.2	(3.74)	+165%	0.0102
MIP-3 β (CCL-19) [pg/ml]	409	(36.6)	643	(42.3)	+57%	0.0004	8.60	(5.02)	24.8	(7.13)	+188%	0.0771
Cytokines (type-1)												
IFN- γ [pg/ml]	n/d		0.63	(0.63)	-	0.3282	7.90	(2.36)	15.2	(3.22)	+92%	0.0812
IL-12p70 [pg/ml]	n/d		n/d		-	-	39.3	(15.1)	90.3	(23.6)	+130%	0.0825
OPN (SPP-1) [ng/ml]	91.5	(7.29)	212	(19.5)	+132%	< 0.0001	n/m		n/m		-	-
Cytokines (type-2)												
IL-4 [pg/ml]	n/d		n/d		-	-	30.3	(6.22)	44.7	(6.94)	+47%	0.1383
IL-5 [pg/ml]	33.0	(25.1)	37.5	(19.1)	+14%	0.1674	21.3	(6.25)	43.8	(13.7)	+106%	0.1485
Cytokines (type-3)												
IL-17 [pg/ml]	n/d		n/d		-	-	8.30	(2.61)	18.8	(3.71)	+127%	0.0294
Pleiotropic cytokines												
GM-CSF (CSF-2) [pg/ml]	n/d		n/d		-	-	0.90	(0.25)	1.85	(0.35)	+106%	0.0377
IL-2 [pg/ml]	n/d		n/d		-	-	10.2	(1.81)	14.6	(2.85)	+43%	0.2056
IL-3 [pg/ml]	n/d		n/d		-	-	n/d		0.18	(0.18)	-	0.3282
IL-7 [pg/ml]	17.0	(11.6)	7.10	(6.31)	-58%	0.4606	18.8	(6.30)	47.3	(9.94)	+152%	0.0244
IL-10 [pg/ml]	379	(20.5)	442	(14.2)	+17%	0.0201	153	(19.6)	209	(15.1)	+36%	0.0351
TNF superfamily												
TNF- α [pg/ml]	29.6	(8.27)	12.3	(3.57)	-58%	0.0677	n/d		1.70	(1.21)	-	0.1666
CD40L [pg/ml]	902	(102)	551	(82.6)	-39%	0.0136	24.3	(19.0)	114	(45.7)	+369%	0.0759
CD40 [pg/ml]	158	(8.76)	251	(21.9)	+59%	0.0007	1.29	(0.71)	8.15	(2.93)	+531%	0.0277
IL-6 like cytokines												
IL-6 [pg/ml]	n/d		n/d		-	-	1.10	(0.49)	2.43	(0.68)	+120%	0.1258
IL-11 [pg/ml]	13.0	(4.73)	17.0	(5.59)	+31%	0.5903	0.92	(0.92)	11.2	(2.74)	+1118%	0.0018
LIF [pg/ml]	94.1	(16.9)	72.4	(5.90)	-23%	0.2397	5.53	(2.20)	16.5	(3.34)	+199%	0.0116
OSM [pg/ml]	17.6	(12.4)	4.90	(2.72)	-72%	0.3279	8.30	(3.39)	33.1	(8.12)	+299%	0.0102
IL-1 family												
IL-1 α [pg/ml]	959	(45.2)	646	(56.6)	-33%	0.0003	298	(47.7)	248	(24.8)	-17%	0.3642
IL-1 β [ng/ml]	1.26	(0.06)	1.39	(0.05)	+10%	0.1098	0.05	(0.03)	0.10	(0.04)	+90%	0.3678
IL-18 [pg/ml]	1.43	(0.04)	2.27	(0.20)	+58%	0.0005	0.07	(0.03)	0.18	(0.04)	+162%	0.0193
Growth factors												
EGF [pg/ml]	18.2	(2.33)	26.3	(1.75)	+44%	0.0111	8.53	(2.51)	7.62	(2.16)	-11%	0.7841
FGF-9 [ng/ml]	0.23	(0.23)	n/d		-	0.3282	0.60	(0.15)	1.70	(0.28)	+182%	0.0021
FGF-b (FGF-2) [ng/ml]	1.43	(0.05)	1.49	(0.03)	+4%	0.3317	0.77	(0.05)	0.94	(0.06)	+22%	0.0525
Growth Hormone [ng/ml]	18.6	(2.76)	63.6	(9.31)	+241%	0.0001	0.13	(0.13)	0.33	(0.18)	+150%	0.3790
M-CSF (CSF-1) [ng/ml]	3.25	(0.10)	2.98	(0.13)	-8%	0.1200	0.05	(0.01)	0.09	(0.01)	+68%	0.0289
SCF (Kitl) [pg/ml]	75.8	(5.66)	98.2	(5.40)	+29%	0.0092	10.7	(3.28)	24.3	(5.05)	+127%	0.0349
TPO [ng/ml]	16.1	(0.36)	14.9	(0.58)	-7%	0.1024	0.40	(0.18)	2.15	(0.36)	+440%	0.0003
VEGF-A [ng/ml]	0.28	(0.03)	0.18	(0.01)	-36%	0.0051	1.50	(0.22)	1.11	(0.12)	-28%	0.1136

Supplementary table 2) Comparison of disease parameters and analyte concentrations in serum and saliva (continuation)

	Serum						Saliva					
	Strain					t-test (sig. 2- tailed)	Strain					t-test (sig. 2- tailed)
	Balb/c	SEM	NOD	SEM	Change		Balb/c	SEM	NOD	SEM	Change	
Peptide hormones	Mean	SEM	Mean	SEM	Change		Mean	SEM	Mean	SEM	Change	
Leptin [pg/ml]	643	(141)	607	(113)	-6%	0.8441	n/d		5.40	(2.44)	-	0.0374
Endothelin-1 [pg/ml]	40.0	(7.38)	65.8	(6.92)	+64%	0.0184	5.72	(1.14)	6.93	(1.47)	+21%	0.5224
Insulin [mIU/ml]	2.63	(0.13)	3.88	(0.12)	+48%	< 0.0001	0.61	(0.12)	0.51	(0.10)	-17%	0.5025
Acute-phase reactants												
CRP [μ g/ml]	1.50	(0.11)	2.77	(0.16)	+85%	< 0.0001	0.03	(0.01)	0.03	(0.01)	-6%	0.8487
Haptoglobin [μ g/ml]	18.9	(0.87)	21.6	(0.82)	+14%	0.0359	1.50	(0.32)	2.29	(0.64)	+53%	0.2584
SAP [μ g/ml]	17.5	(1.01)	25.0	(0.94)	+43%	< 0.0001	0.13	(0.03)	0.13	(0.03)	+0%	0.9965
SGOT [μ g/ml]	15.4	(1.00)	20.4	(1.33)	+33%	0.0062	38.5	(8.45)	40.7	(7.46)	+6%	0.8487
Coagulation factors												
Factor III [ng/ml]	1.93	(0.20)	2.78	(0.26)	+45%	0.0173	0.20	(0.05)	0.28	(0.06)	+40%	0.3069
Factor VII [ng/ml]	1.83	(0.27)	2.83	(0.22)	+54%	0.0092	0.38	(0.04)	0.43	(0.04)	+13%	0.3914
Fibrinogen [μ g/ml]	34.0	(20.0)	404	(67.3)	+1088%	< 0.0001	318	(87.5)	216	(61.7)	-32%	0.4255
vWF [ng/ml]	34.8	(2.00)	33.3	(2.73)	-4%	0.6616	0.26	(0.06)	0.39	(0.08)	+50%	0.1965
Adhesion molecules												
VCAM-1 [ng/ml]	966	(32.6)	1,342	(54.7)	+39%	< 0.0001	0.15	(0.03)	0.22	(0.02)	+49%	0.0424
Proteases and inhibitors												
MMP-9 [ng/ml]	73.5	(9.91)	44.4	(5.35)	-40%	0.0170	40.5	(7.02)	69.7	(9.15)	+72%	0.0191
TIMP-1 [ng/ml]	1.22	(0.30)	1.49	(0.10)	+23%	0.3933	0.10	(0.01)	0.16	(0.02)	+58%	0.0444
Cystatin-C [ng/ml]	506	(22.6)	790	(29.0)	+56%	< 0.0001	n/m		n/m		-	-
Innate immunity												
MPO [ng/ml]	60.8	(3.06)	102	(8.11)	+67%	0.0001	39.9	(8.43)	78.5	(10.8)	+97%	0.0100
NGAL [ng/ml]	n/d		n/d		-	-	n/m		n/m		-	-
Miscellaneous												
Apo A1 [μ g/ml]	52.6	(1.55)	63.3	(2.70)	+20%	0.0024	0.48	(0.06)	0.385	(0.08)	-20%	0.3281
B ₂ m [ng/ml]	333	(96.2)	409	(116)	+23%	0.6194	n/m		n/m		-	-
Calbindin [pg/ml]	317	(176)	670	(377)	+111%	0.4046	n/m		n/m		-	-
Clusterin [μ g/ml]	202	(5.07)	199	(9.32)	-1%	0.7919	n/m		n/m		-	-
GST- α [pg/ml]	137	(44.4)	252	(214)	+83%	0.6068	12.5	(12.5)	59.1	(40.6)	+373%	0.2678
GST-Mu [ng/ml]	n/d		n/d		-	-	n/m		n/m		-	-
Myoglobin [ng/ml]	824	(229)	1,318	(362)	+60%	0.2607	0.14	(0.04)	0.15	(0.03)	+14%	0.7143
IgA [μ g/ml]	137	(5.85)	64.9	(2.96)	-53%	< 0.0001	9.13	(2.72)	9.68	(1.52)	+6%	0.8701
Autoantibodies												
anti-Insulin [U]	2.48	(0.34)	5.28	(1.95)	+112%	0.1731	0.71	(0.02)	0.93	(0.12)	+32%	0.0415
anti-M3R IgG [% pos.]	16.0	(0.75)	23.5	(5.71)	+47%	0.2048	n/m		n/m		-	-
anti-M3R IgG1 [% pos.]	0.53	(0.13)	9.77	(2.76)	+1756%	0.0029	n/m		n/m		-	-
anti-M3R IgG2b [% pos.]	1.58	(0.09)	17.7	(4.57)	+1023%	0.0019	n/m		n/m		-	-
anti-M3R IgG2c [% pos.]	0.91	(0.07)	70.5	(7.10)	+7628%	< 0.0001	n/m		n/m		-	-
anti-M3R IgG3 [% pos.]	0.25	(0.07)	0.54	(0.09)	+114%	0.0219	n/m		n/m		-	-
SSA (anti-Ro) [U]	1.03	(0.41)	0.45	(0.26)	-56%	0.2464	-1.2	(0.19)	-0.2	(0.53)	-79%	0.0696
SSB (anti-La) [U]	2.12	(0.26)	1.95	(0.24)	-8%	0.6466	0.71	(0.02)	0.85	(0.06)	+20%	0.0155
anti-RNP [U]	5.68	(0.69)	55.7	(42.1)	+882%	0.2474	0.56	(0.03)	0.83	(0.12)	+46%	0.0174
anti-pCNA [U]	1.70	(0.17)	1.76	(0.24)	+4%	0.8314	0.74	(0.02)	0.81	(0.05)	+10%	0.1278
anti-Proteinase 3 [U]	1.65	(0.17)	1.69	(0.12)	+2%	0.8603	0.64	(0.04)	0.80	(0.09)	+25%	0.0777
anti-Sm [U]	2.58	(0.59)	401	(200)	15432%	0.0586	0.73	(0.02)	2.56	(1.52)	+252%	0.1505
anti-beta 2GPI [U]	8.98	(2.02)	9.21	(2.76)	+3%	0.9463	0.55	(0.03)	0.86	(0.13)	+56%	0.0117
anti-MPO [U]	3.87	(0.55)	3.32	(1.08)	-14%	0.6556	0.36	(0.03)	0.42	(0.06)	+18%	0.3188
anti-Jo1 [U]	0.57	(0.12)	0.64	(0.10)	+13%	0.6374	0.34	(0.05)	0.58	(0.11)	+69%	0.0548
anti-Mitochondrial [U]	3.80	(0.71)	3.47	(0.60)	-9%	0.7217	0.35	(0.04)	0.61	(0.13)	+72%	0.0392
anti-SCL70 [U]	11.6	(2.41)	8.93	(1.41)	-23%	0.3581	0.87	(0.01)	1.22	(0.12)	+40%	0.0021
anti-Ribosomal P [U]	2.15	(0.21)	1.75	(0.17)	-19%	0.1572	0.55	(0.04)	0.66	(0.11)	+19%	0.3113

Salivary flow is expressed as μ l saliva secreted per minute normalized per gram bodyweight, focus score is the number of foci with 50 or more mononuclear cells per mm^2 glandular tissue and the ratio index represents the area of inflamed tissue per area of glandular tissue. Standard error of the mean (SEM) is displayed parentheses. Significant differences between the means are filled with red. Abbreviations not introduced in the main manuscript: B2m (beta-2 microglobulin), GST (glutathione S-transferase), Jo-1 (histidyl-RNA synthetase), NGAL (lipocalin-2), pCNA (proliferating cell nuclear antigen), Sm (Smith), RNP (ribonuclear protein), TNF (tumor necrosis factor).

Supplementary table 3) Principal component analyses - component structure and loadings

Serum					
Chemokines	1	2	3		
MCP-1 (CCL-2)	0.94	0.24	0.11		
MCP-3 (CCL-7)	0.90	0.38	0.06		
MIP-2 (CXCL-2)	0.84	-0.27	-0.03		
IP-10 (CXCL-10)	0.79	0.24	0.30		
MIP-1 α (CCL-3)	0.14	0.87	0.35		
MIP-1 γ (CCL-9)	-0.08	0.85	0.09		
MCP-5 (CCL-12)	0.39	0.82	-0.14		
MIP-3 β (CCL-19)	-0.19	0.22	0.89		
LTN (XCL-1)	0.47	0.12	0.74		
MDC (CCL-22)	0.58	-0.15	0.66		
Variance explained:	38%	26%	20%		
			84%		
Growth factors	1	2	3		
VEGF-A	0.97	0.04	-0.09		
SCF (Kitl)	0.93	0.17	0.20		
M-CSF (CSF-1)	-0.06	0.93	0.18		
Growth Hormone	0.34	0.86	0.13		
EGF	0.05	0.21	0.97		
Variance explained:	39%	33%	21%		
			93%		
Saliva					
CCL & XCL chemokines	1	2			
LTN (XCL-1)	0.98	0.12			
MCP-3 (CCL-7)	0.96	0.17			
MIP-1 β (CCL-4)	0.96	0.19			
MCP-1 (CCL-2)	0.94	0.25			
RANTES (CCL-5)	0.67	0.30			
Eotaxin (CCL-11)	0.20	0.91			
MDC (CCL-22)	0.18	0.91			
Variance explained:	60%	27%			
			87%		
Cytokines	1	2	3		
IFN- γ	0.98	-0.13	0.05		
IL-7	0.96	0.20	0.14		
OSM	0.94	0.14	0.23		
GM-CSF (CSF-2)	0.89	-0.14	0.40		
IL-17	0.86	-0.03	0.48		
IL-11	0.82	0.39	0.36		
IL-5	0.64	0.28	0.17		
IL-18	0.62	-0.11	0.60		
LIF	0.13	0.98	-0.04		
IL-10	0.12	0.97	0.06		
IL-1 β	-0.08	0.88	0.32		
CD40	0.23	0.16	0.96		
CD40L	0.47	0.38	0.77		
Variance explained:	47%	24%	20%		
			91%		
Autoantibodies	1	2			
anti-RNP	0.99	0.01			
anti-Insulin	0.97	0.14			
anti-Mitochondrial	0.96	0.12			
SSB (anti-La)	0.95	0.26			
anti-SCL70	0.86	0.47			
anti-beta 2GPI	0.12	0.99			
Variance explained:	75%	22%			
			97%		
Cytokines	1	2	3	4	5
OPN (SPP-1)	0.94	-0.07	-0.29	0.01	0.03
LIF	0.74	0.33	0.33	-0.34	-0.23
IL-1 α	0.06	-0.94	0.25	-0.08	-0.02
CD40L	0.45	0.68	0.03	0.34	0.31
CD40	-0.11	-0.22	0.95	-0.06	-0.12
IL-10	-0.09	0.16	-0.06	0.96	-0.04
IL-18	-0.05	0.10	-0.11	-0.03	0.97
Variance explained:	24%	22%	17%	17%	16%
					95%
Coagulation factors	1	2			
Factor VII	0.96	-0.10			
Factor III	0.89	0.33			
Fibrinogen	0.07	0.99			
Variance explained:	57%	37%			
				94%	
CXCL chemokines	1	2			
GRO (CXCL-1)	0.92	-0.08			
MIP-2 (CXCL-2)	0.90	0.05			
IP-10 (CXCL-10)	0.78	-0.55			
GCP-2 (CXCL-5)	0.73	0.64			
Variance explained:	48%	39%			
				88%	
Growth factors	1	2			
SCF (Kitl)	0.93	-0.34			
FGF-9	0.90	-0.40			
TPO	0.61	0.55			
M-CSF (CSF-1)	0.46	0.74			
Variance explained:	49%	35%			
				84%	
Acute-phase reactants	1				
CRP	0.99				
SAP	0.97				
SGOT	0.97				
Variance explained:	95%				
				95%	
Coagulation factors	1	2			
Factor III	0.99	-0.06			
vWF	-0.74	-0.65			
Fibrinogen	-0.01	0.99			
Variance explained:	51%	47%			
				98%	


Yellow fill indicates significant positive factor loading, green fill significant negative factor loading. The percentage of variances explained (extraction sums of squared loadings) by the component is indicated at the bottom of the column together with cumulative variance explained by all components (bold). In saliva, CCL and XCL and CXCL chemokines were separately investigated in saliva to improve the comprehensibility of the model.

Supplementary table 4) Strain membership prediction by defining variables from principal components

Components serum	R*	Speci- ficity	Sensi- tivity	Hit rate
Growth factor Se-C-1	0.883	100%	92%	96%
Cytokine Se-C-1	0.832	92%	100%	96%
Chemokine Se-C-2	0.821	83%	92%	88%
Growth factor Se-C-2	0.794	75%	92%	83%
Chemokine Se-C-1	0.782	75%	100%	88%
Cytokine Se-C-2	0.774	92%	75%	83%
Chemokine Se-C-3	0.772	92%	83%	88%
Coagulation factor Se-C-2	0.747	83%	100%	92%
Cytokine Se-C-5	0.653	75%	100%	88%
Cytokine Se-C-3	0.645	67%	92%	79%
Coagulation factor Se-C-1	0.532	83%	67%	75%
Growth factor Se-C-3	0.509	75%	67%	71%
Cytokine Se-C-4	0.471	75%	83%	79%
Components saliva				
CCL; XCL Sa-C-1	0.880	67%	100%	83%
CXCL Sa-C-1	0.877	92%	100%	96%
Growth factor Sa-C-1	0.799	58%	100%	79%
CXCL Sa-C-2	0.745	75%	92%	83%
Autoantibody Sa-C-1	0.721	63%	100%	85%
Cytokine Sa-C-1	0.678	58%	67%	63%
Cytokine Sa-C-2	0.556	67%	58%	63%
Autoantibody Sa-C-2	0.551	50%	83%	70%
CCL; XCL Sa-C-2	0.539	58%	75%	67%
Cytokine Sa-C-3	0.467	45%	75%	61%
Growth factor Sa-C-2	0.446	58%	67%	63%
Coagulation factor Sa-C-1	0.393	58%	50%	54%
Coagulation factor Sa-C-2	0.281	57%	58%	58%
Acute-phase reac. Sa-C-1	0.205	14%	33%	26%

Results from DA sorted corresponding to their canonical correlation and ranked the principal components according to their capacity to predict strain-membership. Defining variables of the corresponding component were entered simultaneously for DA. Specificity (percentage of correct predictions in the NOD group), sensitivity (percentage of correct predictions in the Balb/c group) and hit ratio (% of correctly classified cases) represent results obtained from cross-validated (leave-one-out) group prediction analyses.

Supplementary figure 1) Extraglandular disease manifestations in the kidneys and the lungs present in a subset of NOD mice



Histopathology of the kidneys (A-C) and the lungs (D-F). A) Mononuclear cell infiltration in the kidney (H&E); B) presence of a hyaline cast in a renal tubulus, (PAS); C) * increased numbers of mesangial cells within the glomerulus, ** hyaline material within glomerular capillaries (PAS); D) * intraalveolar macrophages ** peribronchial lymphocytic infiltrate (H&E); E) foamy macrophages in absence of mononuclear cell infiltration (H&E); F) peripheral lymphocytic infiltrate (H&E). The scale bar represents 100μm; H&E = haematoxylin and eosin; PAS = periodic acid-Schiff staining.

References supplementary table 1)

1. Tornwall J, Lane TE, Fox RI, Fox HS: **T cell attractant chemokine expression initiates lacrimal gland destruction in nonobese diabetic mice.** *Lab Invest* 1999, **79**:1719-1726.
2. Szodoray P, Alex P, Jonsson MV, Knowlton N, Dozmorov I, Nakken B, Delaleu N, Jonsson R, Centola M: **Distinct profiles of Sjögren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF.** *Clin Immunol* 2005, **117**:168-176.
3. Szodoray P, Alex P, Brun JG, Centola M, Jonsson R: **Circulating cytokines in primary Sjögren's syndrome determined by a multiplex cytokine array system.** *Scand J Immunol* 2004, **59**:592-599.
4. Cuello C, Palladinetti P, Tedla N, Di Girolamo N, Lloyd AR, McCluskey PJ, Wakefield D: **Chemokine expression and leucocyte infiltration in Sjögren's syndrome.** *Br J Rheumatol* 1998, **37**:779-783.
5. Lodde BM, Mineshiba F, Wang J, Cotrim AP, Afione S, Tak PP, Baum BJ: **Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjögren's syndrome.** *Ann Rheum Dis* 2006, **65**:195-200.
6. Streckfus C, Bigler L, Navazesh M, Al-Hashimi I: **Cytokine concentrations in stimulated whole saliva among patients with primary Sjögren's syndrome, secondary Sjögren's syndrome, and patients with primary Sjögren's syndrome receiving varying doses of interferon for symptomatic treatment of the condition: a preliminary study.** *Clin Oral Investig* 2001, **5**:133-135.
7. Fox RI, Kang HI, Ando D, Abrams J, Pisa E: **Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome.** *J Immunol* 1994, **152**:5532-5539.
8. De Vita S, Dolcetti R, Ferraccioli G, Pivetta B, De Re V, Gloghini A, D'Agosto A, Bartoli E, Carbone A, Boiocchi M: **Local cytokine expression in the progression toward B cell malignancy in Sjögren's syndrome.** *J Rheumatol* 1995, **22**:1674-1680.
9. Jones DT, Monroy D, Ji Z, Atherton SS, Pflugfelder SC: **Sjögren's syndrome: cytokine and Epstein-Barr viral gene expression within the conjunctival epithelium.** *Invest Ophthalmol Vis Sci* 1994, **35**:3493-3504.
10. Kolkowski EC, Reth P, Pelusa F, Bosch J, Pujol-Borrell R, Coll J, Jaraquemada D: **Th1 predominance and perforin expression in minor salivary glands from patients with primary Sjögren's syndrome.** *J Autoimmun* 1999, **13**:155-162.
11. Jonsson MV, Delaleu N, Brokstad KA, Berggreen E, Skarstein K: **Impaired salivary gland function in NOD mice: association with changes in cytokine profile but not with histopathologic changes in the salivary gland.** *Arthritis Rheum* 2006, **54**:2300-2305.
12. Cha S, Brayer J, Gao J, Brown V, Killedar S, Yasunari U, Peck AB: **A dual role for interferon-gamma in the pathogenesis of Sjögren's syndrome-like autoimmune exocrinopathy in the nonobese diabetic mouse.** *Scand J Immunol* 2004, **60**:552-565.
13. Gao J, Killedar S, Cornelius JG, Nguyen C, Cha S, Peck AB: **Sjögren's syndrome in the NOD mouse model is an interleukin-4 time-dependent, antibody isotype-specific autoimmune disease.** *J Autoimmun* 2006, **26**:90-103.
14. Brayer JB, Cha S, Nagashima H, Yasunari U, Lindberg A, Diggs S, Martinez J, Goa J, Humphreys-Beher MG, Peck AB: **IL-4-dependent effector phase in autoimmune exocrinopathy as defined by the NOD.IL-4-gene knockout mouse model of Sjögren's syndrome.** *Scand J Immunol* 2001, **54**:133-140.

15. Kok MR, Yamano S, Lodde BM, Wang J, Couwenhoven RI, Yakar S, Voutetakis A, Leroith D, Schmidt M, Afione S *et al*: **Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjögren's syndrome.** *Hum Gene Ther* 2003, **14**:1605-1618.
16. Goules A, Tzioufas AG, Manousakis MN, Kirou KA, Crow MK, Routsias JG: **Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases.** *J Autoimmun* 2006, **26**:165-171.
17. Dimitriou ID, Kapsogeorgou EK, Moutsopoulos HM, Manoussakis MN: **CD40 on salivary gland epithelial cells: high constitutive expression by cultured cells from Sjögren's syndrome patients indicating their intrinsic activation.** *Clin Exp Immunol* 2002, **127**:386-392.
18. Eriksson P, Andersson C, Ekerfelt C, Ernerudh J, Skogh T: **Relationship between serum levels of IL-18 and IgG1 in patients with primary Sjögren's syndrome, rheumatoid arthritis and healthy controls.** *Clin Exp Immunol* 2004, **137**:617-620.
19. Bombardieri M, Barone F, Pittoni V, Alessandri C, Conigliaro P, Blades MC, Priori R, McInnes IB, Valesini G, Pitzalis C: **Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjögren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate.** *Arthritis Res Ther* 2004, **6**:R447-456.
20. Koski H, Konttinen YT, Hietanen J, Tervo T, Malmstrom M: **Epidermal growth factor, transforming growth factor-alpha, and epidermal growth factor receptor in labial salivary glands in Sjögren's syndrome.** *J Rheumatol* 1997, **24**:1930-1935.
21. Robinson CP, Yamamoto H, Peck AB, Humphreys-Beher MG: **Genetically programmed development of salivary gland abnormalities in the NOD (nonobese diabetic)-scid mouse in the absence of detectable lymphocytic infiltration: a potential trigger for sialoadenitis of NOD mice.** *Clin Immunol Immunopathol* 1996, **79**:50-59.
22. Boras VV, Cikes N, Lukac J, Cekic-Arambasin A, Virag M, Bosnjak A: **The significance of salivary and serum interleukin 6 and basic fibroblast growth factor levels in patients with Sjögren's syndrome.** *Coll Antropol* 2004, **28 Suppl 2**:305-309.
23. Denko CW, Boja B, Malesud CJ: **Intra-erythrocyte deposition of growth hormone in rheumatic diseases.** *Rheumatol Int* 2003, **23**:11-14.
24. Moutsopoulos HM, Elkon KB, Mavridis AK, Acritidis NC, Hughes GR, Pepys MB: **Serum C-reactive protein in primary Sjögren's syndrome.** *Clin Exp Rheumatol* 1983, **1**:57-58.
25. Youinou P, Fauquert P, Penneec YL, Bendaoud B, Katsikis P, Le Goff P: **Raised C-reactive protein response in rheumatoid arthritis patients with secondary Sjögren's syndrome.** *Rheumatol Int* 1990, **10**:39-41.
26. Saso L, Silvestrini B, Guglielmotti A, Lahita R, Cheng CY: **Abnormal glycosylation of alpha 2-macroglobulin, a non-acute-phase protein in patients with autoimmune diseases.** *Inflammation* 1993, **17**:465-479.
27. Ryo K, Yamada H, Nakagawa Y, Tai Y, Obara K, Inoue H, Mishima K, Saito I: **Possible involvement of oxidative stress in salivary gland of patients with Sjögren's syndrome.** *Pathobiology* 2006, **73**:252-260.
28. Oxholm P, Oxholm A, Manthorpe R: **Epidermal Langerhans cells in patients with primary Sjögren's syndrome.** *Allergy* 1986, **41**:429-434.
29. Blann AD, Hopkins J, Winkles J, Wainwright AC: **Plasma and serum von Willebrand factor antigen concentrations in connective tissue disorders.** *Ann Clin Biochem* 1992, **29 (Pt 1)**:67-71.

30. Cuida M, Halse AK, Johannessen AC, Tynning T, Jonsson R: **Indicators of salivary gland inflammation in primary Sjögren's syndrome.** *Eur J Oral Sci* 1997, **105**:228-233.
31. Turkcapar N, Sak SD, Saatci M, Duman M, Olmez U: **Vasculitis and expression of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and E-selectin in salivary glands of patients with Sjögren's syndrome.** *J Rheumatol* 2005, **32**:1063-1070.
32. Mikulowska-Mennis A, Xu B, Berberian JM, Michie SA: **Lymphocyte migration to inflamed lacrimal glands is mediated by vascular cell adhesion molecule-1/alpha(4)beta(1) integrin, peripheral node addressin/l-selectin, and lymphocyte function-associated antigen-1 adhesion pathways.** *Am J Pathol* 2001, **159**:671-681.
33. Hulkkonen J, Pertovaara M, Anttonen J, Pasternack A, Hurme M, Pollanen P, Lehtimäki T: **Matrix metalloproteinase 9 (MMP-9) gene polymorphism and MMP-9 plasma levels in primary Sjögren's syndrome.** *Rheumatology (Oxford)* 2004, **43**:1476-1479.
34. Azuma M, Aota K, Tamatani T, Motegi K, Yamashita T, Harada K, Hayashi Y, Sato M: **Suppression of tumor necrosis factor alpha-induced matrix metalloproteinase 9 production by the introduction of a super-repressor form of inhibitor of nuclear factor kappaB/alpha complementary DNA into immortalized human salivary gland acinar cells. Prevention of the destruction of the acinar structure in Sjögren's syndrome salivary glands.** *Arthritis Rheum* 2000, **43**:1756-1767.
35. Asatsuma M, Ito S, Watanabe M, Takeishi H, Nomura S, Wada Y, Nakano M, Gejyo F, Igarashi A: **Increase in the ratio of matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 in saliva from patients with primary Sjögren's syndrome.** *Clin Chim Acta* 2004, **345**:99-104.
36. Perez P, Kwon YJ, Alliende C, Leyton L, Aguilera S, Molina C, Labra C, Julio M, Leyton C, Gonzalez MJ: **Increased acinar damage of salivary glands of patients with Sjögren's syndrome is paralleled by simultaneous imbalance of matrix metalloproteinase 3/tissue inhibitor of metalloproteinases 1 and matrix metalloproteinase 9/tissue inhibitor of metalloproteinases 1 ratios.** *Arthritis Rheum* 2005, **52**:2751-2760.
37. Yamachika S, Nanni JM, Nguyen KH, Garces L, Lowry JM, Robinson CP, Brayer J, Oxford GE, da Silveira A, Kerr M *et al*: **Excessive synthesis of matrix metalloproteinases in exocrine tissues of NOD mouse models for Sjögren's syndrome.** *J Rheumatol* 1998, **25**:2371-2380.
38. Cha S, van Blockland SC, Versnel MA, Homo-Delarche F, Nagashima H, Brayer J, Peck AB, Humphreys-Beher MG: **Abnormal organogenesis in salivary gland development may initiate adult onset of autoimmune exocrinopathy.** *Exp Clin Immunogenet* 2001, **18**:143-160.
39. Ryu OH, Atkinson JC, Hoehn GT, Illei GG, Hart TC: **Identification of parotid salivary biomarkers in Sjögren's syndrome by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry and two-dimensional difference gel electrophoresis.** *Rheumatology (Oxford)* 2006, **45**:1077-1086.
40. Ludviksdóttir D, Janson C, Hogman M, Gudbjörnsson B, Björnsson E, Valtýsdóttir S, Hedenström H, Venge P, Boman G: **Increased nitric oxide in expired air in patients with Sjögren's syndrome. BHR study group. Bronchial hyperresponsiveness.** *Eur Respir J* 1999, **13**:739-743.
41. Navone R, Lunardi C, Gerli R, Tinazzi E, Peterlana D, Bason C, Corrocher R, Puccetti A: **Identification of tear lipocalin as a novel autoantigen target in Sjögren's syndrome.** *J Autoimmun* 2005, **25**:229-234.

42. Lodde BM, Sankar V, Kok MR, Leakan RA, Tak PP, Pillemer SR: **Serum lipid levels in Sjögren's syndrome.** *Rheumatology (Oxford)* 2006, **45**:481-484.
43. Vaudo G, Bocci EB, Shoenfeld Y, Schillaci G, Wu R, Del Papa N, Vitali C, Delle Monache F, Marchesi S, Mannarino E *et al*: **Precocious intima-media thickening in patients with primary Sjögren's syndrome.** *Arthritis Rheum* 2005, **52**:3890-3897.
44. Gottenberg JE, Busson M, Cohen-Solal J, Lavie F, Abbed K, Kimberly RP, Sabilia J, Mariette X: **Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjögren's syndrome.** *Ann Rheum Dis* 2005, **64**:1050-1055.
45. Markusse HM, Huysen JC, Nieuwenhuys EJ, Swaak AJ: **Beta 2 microglobulin in tear fluid from patients with primary Sjögren's syndrome.** *Ann Rheum Dis* 1992, **51**:503-505.
46. Morinobu A, Kanagawa S, Koshiba M, Sugai S, Kumagai S: **Association of the glutathione S-transferase M1 homozygous null genotype with susceptibility to Sjögren's syndrome in Japanese individuals.** *Arthritis Rheum* 1999, **42**:2612-2615.
47. Bendaoud B, Penneç YL, Lelong A, Le Noac'h JF, Magadur G, Jouquan J, Youinou P: **IgA-containing immune complexes in the circulation of patients with primary Sjögren's syndrome.** *J Autoimmun* 1991, **4**:177-184.
48. Rhodus N, Dahmer L, Lindemann K, Rudney J, Mathur A, Bereuter J: **s-IgA and cytokine levels in whole saliva of Sjögren's syndrome patients before and after oral pilocarpine hydrochloride administration: a pilot study.** *Clin Oral Investig* 1998, **2**:191-196.
49. Zandbelt MM, Wentink JR, de Wilde PC, van Damme PA, van de Putte LB, van den Hoogen FH: **The synergistic value of focus score and IgA% score of sublabial salivary gland biopsy for the accuracy of the diagnosis of Sjögren's syndrome: a 10-year comparison.** *Rheumatology (Oxford)* 2002, **41**:819-823.
50. Matsumoto N, Salam MA, Watanabe H, Amagasa T, Senpuku H: **Role of gene E2f1 in susceptibility to bacterial adherence of oral streptococci to tooth surfaces in mice.** *Oral Microbiol Immunol* 2004, **19**:270-276.
51. Dawson LJ, Stanbury J, Venn N, Hasdimir B, Rogers SN, Smith PM: **Antimuscarinic antibodies in primary Sjögren's syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cells.** *Arthritis Rheum* 2006, **54**:1165-1173.
52. Gao J, Cha S, Jonsson R, Opalko J, Peck AB: **Detection of anti-type 3 muscarinic acetylcholine receptor autoantibodies in the sera of Sjögren's syndrome patients by use of a transfected cell line assay.** *Arthritis Rheum* 2004, **50**:2615-2621.
53. Cavill D, Waterman SA, Gordon TP: **Antibodies raised against the second extracellular loop of the human muscarinic M3 receptor mimic functional autoantibodies in Sjögren's syndrome.** *Scand J Immunol* 2004, **59**:261-266.
54. Avaniss-Aghajani E, Berzon S, Sarkissian A: **Clinical value of multiplexed bead-based immunoassays for detection of autoantibodies to nuclear antigens.** *Clin Vaccine Immunol* 2007, **14**:505-509.
55. Halse AK, Marthinussen MC, Wahren-Herlenius M, Jonsson R: **Isotype distribution of anti-Ro/SS-A and anti-La/SS-B antibodies in plasma and saliva of patients with Sjögren's syndrome.** *Scand J Rheumatol* 2000, **29**:13-19.
56. Tengner P, Halse AK, Haga HJ, Jonsson R, Wahren-Herlenius M: **Detection of anti-Ro/SSA and anti-La/SSB autoantibody-producing cells in salivary glands from patients with Sjögren's syndrome.** *Arthritis Rheum* 1998, **41**:2238-2248.
57. Skarstein K, Holmdahl R, Johannessen AC, Goldschmidt T, Jonsson R: **Short-term administration of selected anti-T-cell receptor V beta chain specific MoAb reduces sialadenitis in MRL/lpr mice.** *Scand J Immunol* 1995, **42**:529-534.

58. Ramos-Casals M, Nardi N, Brito-Zeron P, Aguilo S, Gil V, Delgado G, Bove A, Font J: **Atypical autoantibodies in patients with primary Sjögren syndrome: clinical characteristics and follow-up of 82 cases.** *Semin Arthritis Rheum* 2006, **35**:312-321.
59. Tzang BS, Chen TY, Hsu TC, Liu YC, Tsay GJ: **Presentation of autoantibody to proliferating cell nuclear antigen in patients with chronic hepatitis B and C virus infection.** *Ann Rheum Dis* 1999, **58**:630-634.
60. Font J, Ramos-Casals M, Cervera R, Bosch X, Mirapeix E, Garcia-Carrasco M, Morla RM, Ingelmo M: **Antineutrophil cytoplasmic antibodies in primary Sjögren's syndrome: prevalence and clinical significance.** *Br J Rheumatol* 1998, **37**:1287-1291.
61. Cervera R, Garcia-Carrasco M, Font J, Ramos M, Reverter JC, Munoz FJ, Miret C, Espinosa G, Ingelmo M: **Antiphospholipid antibodies in primary Sjögren's syndrome: prevalence and clinical significance in a series of 80 patients.** *Clin Exp Rheumatol* 1997, **15**:361-365.
62. Ikuno N, Mackay IR, Jois J, Omagari K, Rowley MJ: **Antimitochondrial autoantibodies in saliva and sera from patients with primary biliary cirrhosis.** *J Gastroenterol Hepatol* 2001, **16**:1390-1394.
63. Ramos-Casals M, Pares A, Jara LJ, Solans R, Vinas O, Vazquez P, Sanchez-Tapias JM, Rodes J, Font J: **Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: description of 18 cases and review of the literature.** *J Viral Hepat* 2005, **12**:648-654.
64. Goules A, Masouridi S, Tzioufas AG, Ioannidis JP, Skopouli FN, Moutsopoulos HM: **Clinically significant and biopsy-documented renal involvement in primary Sjögren syndrome.** *Medicine (Baltimore)* 2000, **79**:241-249.

